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Background: Recently several studies have focused on the use of magnetic 
resonance imaging (MRI) and biomarkers that might facilitate early diagnosis of 
axial spondyloarthritis (axSpA) and identify individuals at higher risk of developing 
the disease. New biomarkers of inflammation, neo-apposition and bone remodeling 
might be helpful for early axSpA diagnosis and could be used as prognostic factors, 
measures of outcome and indicators of effectiveness of treatment. 
Objectives: The study aimed to identify: 1) potentially useful biomarkers for early 
diagnosis of axSpA and their correlations with disease activity and imaging indices; 
2) the prevalence of spine and pelvis MRI lesions in patients (pts) with low back 
pain (LBP); 3) the correlation between the site of axial pain and of MRI-lesions. 
Material and Methods:Seventy-two pts with LBP (≥3 months, ≤2 years, onset ≤45 
years) underwent a physical examination, questionnaires, laboratory tests, X-rays 
and MRI of the spine and sacroiliac joints (SIJ) at baseline and during a followup 
period of 24 months. Two expert rheumatologists formulated axSpA diagnosis and 
assessed fulfilment of Assessment of SpondyloArthritis International Society 
ASAS criteria. Disease activity and physical functioning were assessed using 
imaging, clinical and serological indices: Bath Ankylosing Spondylitis Metrology 
Index (BASMI);Maastricht Ankylosing enthesitis Spondilities Score 
(MASES);Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);Bath 
Ankylosing Spondylitis Functional Index (BASFI);Ankylosing Spondylitis disease 
activity score (ASDAS);Visual Analogue Scale (VAS pain);VAS night pain;VAS 
disease activity;Bath Ankylosing Spondylitis Patient Global Score 
(BASG1);BASG2;Health Assessment Questionnaire (HAQ);ESR;serum 
ultrasensitive CRP (hs-CRP);matrix metalloproteinase (MMP3);interleukin (IL) 
IL-22, IL-17, IL-23. Spine and SIJ MRI and X-rays were scored independently by 
2 readers following the SPARCC, mSASSS and NY-criteria. The axial pain and 
localization of MRI-lesions were classified into 4 sites: cervical/thoracic/lumbar 
spine and buttocks. The association between the site of pain and MRI-lesions was 




evaluated through Odds Ratio (OR). The Spearman test and Kruskal Wallis test 
were used to compare all indices in these cohorts. 
Results: Patients were diagnosed with axSpA and classified in accordance ASAS 
criteria as: 1) 21 pts classified according to axSpA imaging arm+;2) 29 pts classified 
according to axSpA clinical arm+;3) 25 pts not fulfilling ASAS criteria. The median 
LBP onset was 28.51±8.05 years, 45.3% were male, HLA-B27 was positive in 
38.7% pts. 37.3%, 56%, 64% pts, respectively, complained about 
cervical/thoracic/buttock pain; 56% pts showed bone marrow edema (BME) in 
spine-MRI (19%, 39%, 33% in cervical/thoracic/lumbar region) and 61.3% pts in 
SIJ-MRI (respectively 58% on the right SIJ and 50% on the left SIJ). Signs of 
enthesitis were found in 47 (62.7%) pts (respectively 8%, 58%, 11% in the 
cervical/thoracic/lumbar spine). Eigtheen (24%) pts presented a negative BME SIJ-
MRI with a positive BME spine-MRI. OR between site of pain and site of BME 
lesions was 20.78 (p=NS), 163.93 (p=0.0006); 0.34 (p=NS) for 
cervical/thoracic/lumbar spine and 304.88 (p=0.0203) for buttocks. A significant 
correlation between thoracic pain/ enthesitis on thoracic district (OR=32.69;p= 
0.0336) was also found. There was a significant difference between the three 
cohorts with regard to the prevalence of radiographic sacroiliitis, active sacroiliitis 
on MRI and the SPARCC SIJ score. There were no differences in these groups 
regarding IL-17, IL-22, IL-23, MMP-3 and hsCRP. There was found a correlation 
between IL-22 and some clinical indices (BASFI, BASG1,HAQ,VAS pain). The 
correlation between mSASSS, MMP3 and hsCRP was an interesting finding.  
Conclusions:The site of pain correlated in a statistically significant manner with 
BME lesions in thoracic and buttock districts. Since positive spine-MRI images 
were observed in absence of sacroiliitis, we can be therefore hyphothezise that this 
finding could have a diagnostic significance in suspected axSpA. Although not 
significantly higher in any of the three groups, IL-22, MMP3 and hsCRP values 
correlated with some disease activity indices and with mSASSS. Larger 
observational studies are warranted to confirm these preliminary findings. 






1.1.1 GENERAL ASPECTS 
Spondyloarthropathies (SpA) are a heterogeneous group of chronic, inflammatory, 
rheumatic disorders characterized by overlapping clinical signs and symptoms and 
a common genetic background [1-3]. The prevalence is about 2% in the general 
population. The concept of SpA, introduced in 1976 by Wright and Moll [4-5], was 
born with the intention of bringing together in the same group different 
eterogeneous diseases, united by some similar clinical and radiological aspects. The 
SpA have in common the frequent association with the "Human Leucocyte 
Antigen" HLA-B27, the absence of the rheumatoid factor, the peripheral 
inflammatory arthritis, usually asymmetric and more frequent in the lower limbs, 
the sacroiliitis, the enthesitis (inflammation of the particular anatomic area of 
insertion of tendons, ligaments and capsules on the bone), in addition to a frequent 
family aggregation [6-8]. Apart from common articular and spinal symptoms, there 
is also an overlap of skin, eye, and gut manifestations, such as some cutaneous 
lesions (psoriasis, pustulosis, keratodermia blenorragica, erythema nodosum, 
pyoderma gangrenose), mucositis (oral, intestinal, genital ulcers), uveitis and 
inflammatory bowel disease. SpA patients present with pain, morning stiffness and 
disability. Depending on the predominant pattern of clinical symptoms, SpA can be 
divided into SpA with a prevalent axial involvement (axSpA) or prevalently 
peripheral involvement (pSpA). In the first decade of the new millennium 
significant progress has been achieved, especially in the treatment of axSpA, thanks 
to the discovery and diffusion of the use of biotechnological anti-tumor necrosis 
factor α (TNFα) drugs in clinical practice. The need to assess the degree of disease 
activity in these forms is now becoming increasingly important and of common 
interest among rheumatologists, not only in terms of initial diagnosis, but also to 
monitorize response to therapy. Traditional radiography, able to detect bone 
structural alterations such as sacroiliitis, typical manifestation of radiological 




axSpA or ankylosing spondylitis (AS), -according to the modified criteria of New 
York of 1984 [9]-, is a method alone no longer sufficient for an appropriate 
classification of the patient with suspicion of axSpA. In patients with early-onset 
axSpA with no evidence of radiographic damage, nuclear magnetic resonance 
imaging (MRI) may show acute inflammatory lesions before bone structural change 
is established. This category of patients may present a very active disease with axial 
pain symptoms, similarly to patients with AS. In addition, these patients respond 
quickly and effectively to the therapy with anti-TNFα drugs, therefore the 
identification of these forms in the early stage of the disease becomes a priority in 
order to establish the most appropriate treatment, right from the very beginning. 
 
1.1.2 CLASSIFICATION OF SPONDILOARTHRITIS 
SpA are divided into: ankylosing spondylitis (AS), psoriatic arthritis (PsA), arthritis 
associated with inflammatory intestinal diseases (Crohn's disease and ulcerative 
colitis), reactive arthritis (ARe) and undifferentiated forms (uSpA) [10-12] (Table 
I). 
 
Table I. Classification spondylo-entheso-artritis of the adult 
 
Spondylo-entheso-artritis of the adult: 
• Ankylosing spondylitis (AS) 
• Psoriatic arthritis (PsA) 
• Arthritis associated with chronic inflammatory enteritis (enteropathic arthritis) 
o Arthritis of ulcerative colitis 
o Arthritis of Crohn's disease 
• Reactive arthritis 
o Enteroarthritis 
o Uroarthritis 
o Other forms 
• Undifferentiated Spondylo-entheso-artritis (uSpA) 
 
In some cases, however, patients do not fulfill all the necessary criteria to be 
included in one of these forms, and are therefore classified as affected by uSpA. 
The classification according to Amor 1990 criteria (Table II) allows to have a more 
complete list of the main characteristics of these diseases and the subsequent 




classification of the European Spondyloarthropathy Study Group (ESSG) (Table 
III) allowed a better definition of SpA [13-20].  Because of the insidious onset of 
the complaints, a considerable proportion of patients is not recognized using these 
classification criteria at an early stage of disease. With the development of new 
treatment strategies such as the possibly disease modifying therapy with TNF-α 
blocking drugs, the need to identify a patient in an earlier stage of disease increases 
[21-26]. Because of the disease burden, costs involved in searching for a diagnosis 
and the potential therapeutic consequences, it is important to identify these patients 
early in the disease course.  Chronic low back pain is the main musculoskeletal 
complaint of these forms, however only a small proportion of these patients have 




Table II. Amor’s classification criteria for spondyloarthritis, 1990* 
    
 A patient is considered as suffering from spondyloarthritis if the sum is ≥ 6 
*Critères de classification des spondyloarthropathies. Rev Rheum 57:85-9 (1990) 
 
A. Clinical symptoms or past history of score 
1. Lumbar or dorsal pain at night or morning stiffness of lumbar or dorsal pain 1 
2. Asymmetrical oligoarthritis 2 
3. Buttock pain 
If alternate buttock pain 
1 
2 
4. Sausage-like toe or digit 2 
5. Heel pain or other well-defined enthesopathy 2 
6. Iritis 1 
7. Non-gonococcal urethritis or cervicitis within one month before the onset of arthritis 1 
8. Acute diarrhea within one month before the onset of arthritis 1 
9. Psoriasis, balanitis, or inflammatory bowel disease (ulcerative colitis or Crohn’s disease) 2 
B. Radiological findings  
10. Sacroiliitis (bilateral grade 2 or unilateral grade 3) 3 
C. Genetic background  
11. Presence of HLA-B27 and/or family history of ankylosing spondylitis, reactive arthritis, 
uveitis, psoriasis or inflammatory bowel disease 
 
2 
D. Response to treatment  
12. Clear-cut improvement within 48 hours after NSAIDS intake or rapid relapse of the pain 
after their discontinuation 
2 






Table III: ESSG criteria for SpA* 
 
Inflammatory spinal pain 
     OR 
Synovitis (asymmetrical, predominantly in the lower extremities) 
AND 
one of the following: 
- Family history: first- or second-degree relative with AS, spondylitis, psoriasis, 
acute uveitis, reactive arthritis or IBD); 
- Past or present psoriasis diagnosed by a physician; 
- Past or present ulcerative colitis (or Crohn’s disease) diagnosed by a physician 
and confirmed by radiography and/or endoscopy; 
- Past or present pain alternating between the buttocks; 
- Past or present spontaneous pain or tenderness at examination of the site of 
insertion of the Achilles tendon or plantar fascia (enthesitis); 
- Episode of diarrhea occurring  ≤1 month before onset of symptoms; 
- Non-gonococcal urethritis or cervicitis  ≤1 month before onset of symptoms; 
- Bilateral grade 2-4 sacroiliitis or unilateral grade 3 or 4 sacroiliitis 
 
* European Spondyloarthropathy Study Group (1991) 
 
Table IV. Inflammatory low back pain:  
 
Factors which differentiate the back pain produced by spondylitis from the back 
pain due to other causes: 
1. Onset of back pain before the age of 40 years 
2. Insidious onset 
3. Persistence of at least 3 months 
4. Associate with morning stiffness 
5. Improvement with exercise 
6. Good response to anti-inflammatory drugs 
7. Night pain 
 
Moreover, recently the concept of axSpA has been proposed as an entity including 
both AS and its potential pre-stage. Patients with axSpA who still have normal 
radiographs of the sacroiliac joints (SIJ) are therefore defined as non-radiographic 
axial SpA (nr-axSpA) patients. Some of these patients might develop AS with 
radiographic sacroiliitis. However, some patients will be diagnosed as axSpA 
forever, never resulting in AS. It is now well established that a significant amount 
of time can pass from low back pain onset to the presence of radiologically 




detectable sacroiliitis [27,28]. In this regard, the Assessment of SpondyloArthritis 
International Society (ASAS) has developed classification criteria, which 
summarize the results of two decades of studies [29-34]. The innovative role of 
these criteria derives from the fact that they take into consideration many aspects 
of SpA, from familiarity to anamnesis, clinical manifestations and diagnostic and 
laboratory investigations (Figure 1a and 1b). These criteria have been also 
developed to identify patients with early stages of axSpA [31] and the forms that 
potentially present the greatest risk of evolving to AS. For this purpose, it was 
established the inclusion in these criteria of the presence of sacroiliitis on magnetic 
resonance imaging (MRI) with bone marrow oedema (BME) as an expression of 
inflammatory lesion, in addition to one SpA feature for patients with chronic low 
back pain with onset at age ≤45 years [35-46] (Figure 2). In early stages of AS 
inflammatory changes may be seen only on MRI. So, these patients belong to the 
group of nr-axSpA. It is at present unknown if MRI inflammation should be seen 
as an early stage of structural damage that only becomes visible at the radiographs 
at a later stage, or if it does not necessarily lead to structural damage. the role of 
MRI seems important also in measuring disease activity and has to be further 
investigated. The ASAS criteria, published in 2009, are based on the distinction 
between axial or peripheral form, distinguishing the (–prevalently) axSpA and 
(prevalently) pSpA forms, among which PsA, enteropathic arthritis, ARe and uSpA 









Sieper J et al. Ann Rheum Dis.2009 
 
Figure 1a. ASAS classification criteria for axial spondyloarthritis 
 
 Sieper J et al. Ann Rheum Dis.2009 
 
Figure 1b. ASAS classification criteria for peripheral spondyloarthritis 
 
Arthritis° or Enthesitis or 
Dactylitis
plus ≥1 of:                                                                      
* Psoriasis                                                              
* Inflammatory bowel diseases                                                           
* Preceding infections                                         
* HLA B27                                                              
* Uveitis                                                                      
* Sacroiliitis on imaging (radiography or MRI)                                               
plus ≥ 2 of the remaining :                                    
* Arthritis                                                            
* Enthesitis                                                          
* Dactylitis                                                            
* IBP in the past                                                   
* Positive family history for SpA                           
° Arthritis mainly of lower limbs 
and/or asimmetric arthritis








axSpA: Axial Spondyloarthritis.  
Rudwaleit, M., Khan, M. A. &Sieper, J. Arthritis Rheum.52, 1000–1008 (2005); Rudwaleit, M. 
&Sieper, J. Nat. Rev. Rheumatol. 8, 262–268 (2012) 
 
Figure 2. The concept of axSpA: transition from the early phase of the axSpA 
to AS on the basis of the evolution from the non-radiological to the 
radiological stage. 
 
Not all patients present the evolution from the non-radiological stage of the axSpA 
to the radiological stage. The predictors of progression include the duration of 
illness, the severity and intensity of the inflammation detected by the MRI, the male 
gender and other possible indicators, not yet identified. AxSpA usually begins 
without signs of sacroiliitis that can be detected on conventional radiology, but over 
a period of years, the signs of sacroiliitis and spondylitis become radiologically 
evident. Inflammatory back pain is the main symptom, which may persist 
throughout the course of the disease. During the early stages of the disease, MRI 
can highlight acute inflammatory lesions in the absence of radiographic signs of 
sacroiliitis. The vertical dotted line is used, according to the defined criteria, to 
separate the non-radiological axSpA, from AS. 
 
The ASAS criteria for axSpA are divided into two arms: the "imaging" arm or the 
"clinical" arm, both requiring the onset of inflammatory back pain before the age 
of 45 years, with its persistence for at least 3 months (Figure 1a). 
To satisfy the "imaging" arm, the patient must present signs of sacroiliitis, at X-rays 
or MRI, in addition to one of the SpA manifestations. To satisfy the "clinical" arm, 
the patient must present HLA-B27 positivity, in addition to at least two 
manifestations of SpA, while the presence of sacroiliitis is not mandatory.  
AxSpA can also be classified, according to the radiological stage in: non-
radiographic stage I, for the absence of lesions; Stage II, with structural lesions in 
the SIJ and the absence of spinal injuries; Stage III, with SIJ and spinal lesions. 




Previously, early-stage axial SpA forms, without signs of structural radiographic 
lesions, were often included in the uSpA. In the recent classification criteria, the 
term uSpA is abandoned and, due to the absence of structurally evident lesions to 
conventional radiology, this form is referred to as nr-axSpA. Male sex is recognized 
as a risk factor for the evolution of nr-axSpA to AS. The classification of these 
forms of SpA is still in evolution, in particular due to the need to obtain a more 
adequate definition of the diagnostic relevance of the different lesions on imaging 
and due to the recent important role played by MRI in the diagnostic process. 
 
Table V) Nomenclature of SpA according to the ASAS criteria: 
-------------------------------------------------- ---------------------------------- 
a. (predominant) axial spondyloarthritis (axSpA) 
1. non-radiographic axSpA (nr-axSpA) 
2. ankylosing spondylitis (SA) = radiographic axSpA 
both associated with: 
a. psoriasis 
b. inflammatory bowel disease (IBD) 
-------------------------------------------------- ---------- 
b. (predominant) peripheral spondyloarthritis (pSpA) 
1. psoriatic arthritis (AP) and / or pSpA associated with psoriasis 
2. pSpA associated with (IBD) 
a. type I 
b. type II 
3. reactive arthritis (ARe) 
4. undifferentiated peripheral SpA (uSpA) 
------------------------------------------------- 
c. (in case of no real predominance) spondyloarthritis associated with: 
a. psoriasis 
b. inflammatory bowel disease (IBD) 
c. previous infection 












1.2 THE PATHOGENESIS, THE ROLE OF THE GENETIC 
MECHANISMS AND BIOMARKERS IN THE AXIAL 
SPONDYLOARTHRITIS  
 
1.2.1 GENETIC MECHANISMS AND THE PATHOGENESIS 
 
The etiopathology of AS, which has not yet been fully understood, is based on an 
interaction between some genetic, environmental, physical and infective risk 
factors.The genetic basis of AS and the role of Human Leukocyte Antigen (HLA)-
B27 in these patients has been established through several studies [47]. Some have 
shown, in fact, that AS has a strong genetic basis and that a strong genetic 
association exists with major histocompatibility complex (MHC) class I allele 
human leukocyte antigen (HLA)-B27 [48]. It has been estimated that no more than 
5% of HLA-B27-positive Caucasian individuals develop AS, whereas 
approximately 90% of AS patients carry this allele [49]. Knowledge is still 
incomplete with regard to the role of genetic predisposition in the disease’s 
pathogenesis and in the development of other axSpA forms. In fact, HLA-B27 is 
positive in up to 80-90% of AS patients, while the prevalence of this allele is less 
common in nr-axSpA patients (73-75%), although it continues to be helpful in 
diagnosing that form of the disease [50]. A longitudinal study with a mean follow-
up of 7.7 years showed, in fact, that the combination of severe sacroiliitis on MRI 
and HLA-B27 positivity was a predictor of future AS development [51]. The exact 
role of HLA-B27 in axSpA is unclear. The HLA-B27 includes a family of 31 
different alleles; the subtypes HLA-B *2702, B *2704 and B *2705 are closely 
associated with the disease. Therefore several pathogenic mechanisms are 
hypothesized and evaluated in the literature by now [52] (Table VI). Firstly, a 
genetic interaction has been identified between HLA-B27 and a gene encoding an 
enzyme called endoplasmic reticulum aminopeptidase (ERAP1) which processes 
peptides so they can be loaded onto the MHC class I molecules.  ERAP1 variants 
may increase the risk of development of AS and nr-axSpA when HLA-B27 is 




present. These interactions strongly suggest that the mechanism by which HLA-
B27 contributes to the pathogenesis of axSpA is through its antigen presentation 
function forming a complex with β-2 microglobulin (arthritogenic peptide 
hypothesis). Another shared hypothesis is that the specific cytotoxic T lymphocytes 
(CTLs) for a bacterial peptide cross-react with an arthritogenic self-peptide, which 
shares a sequence homology, due to molecular mimicry [47]. Another theory 
suggests that HLA-B27 molecules can be mounted on the cell surface as a pair of 
homologous heavy chains (homodimers) in the absence of β2-microglobulins [53]; 
the newly formed receptor is able to bind a class of molecules present on the cell 
membrane (KIRs, including KIR3DL1, KIR3DL2) determining a hyperactivation 
of the innate immunity cells and inducing the disease [54]. Another mechanism 
proposed to explain the reduced capacity for elimination of pathogens is due to 
misfolding HLA-B27 (abnormal folding of the HLA-B27 heavy chain) with 
subsequent impaired recognition by the effector cells of the immune system [55,56]. 
According to the latter hypothesis, components of the HLA-B27 molecules, 
incompletely assembled in the endoplasmic reticulum (ER), are able to induce an 
unfolded protein response [55] and to trigger an immune response, with IL-23 and 
TNFα production and Th17 cells induction [56,57]. Misfolding can derive from the 
excess of unpaired HLA-B27 molecules, due to an imbalance with respect to the 
expression of those of β2-microglobulins. Additionally, misfolded HLA-B27 could 
also induce other autophagy-associated processes [58]. Beyond the different 
functions of HLA-B27, some investigators have suggested that its expression may 
predispose to developing AS. These patients demonstrate, in fact, a higher 
expression of HLA-B27 in peripheral blood mononuclear cells with respect to that 
in HLAB27-positive healthy individuals [59]. Since it has been estimated that 
HLA-B27 is responsible for 40% of the genetic risk of all forms of axSpA [48,60], 
some studies have examined the contribution of additional genes and some single 
nucleotide polymorphisms (SNPs) to axSpA disease susceptibility identiﬁed by 
genome-wide association studies [61,62]. 
 




Table VI: Theories of possible disease-inducing mechanisms by HLA-B27 
 
Theory Mechanism 
Arthritogenic peptide hypothesis HLA-B27 presents a peptide to CD8 T 
cells through the classical antigen 
presentation function on MCH I 
contributing to the induction of the 
disease 
Endoplasmic reticulum stress hypothesis    Fractions of HLA-B27 proteins 
incompletely assembled (misfolding) in 
the endoplasmic reticulum cause stress, 
consequently they induce disease through 
the production of IL-23 and consequently 
the modulation of oxidative pathways 
Cell surface homodimer hypothesis   HLA-B27 forms homo-dimers on the cell 
surface that interact with innate immunity 
cells inducing the disease 
Immunodeficiency hypothesis               HLA-B27 presents an altered number of 
peptides or with anormal morphology 
determining an inadequate or altered 
degradation and elimination process of 
heterologous microbes peptides 
HLA, human leucocyte antigen; IL, interleukin. 
Robinson PC et al. Internal Medicine Journal 2014 
 
In the HLA-B27 negative axSpA forms, a high prevalence of other HLA-class I 
alleles of the B7-CREG group ("cross-reacting-epitope-group": HLA-B7, -B22, -
B40 and -Bw42) and Bw62 / Bw35 CREG antigens was detected [60-62]. These 
axSpA forms appear to have milder clinical characteristics, with a later onset age, 
associated with lower frequency of uveitis, less family aggregation and less 
development; they are often associated with psoriasis and enteropathy.  
A recent study investigated whether polymorphisms (SNPs) in the promoter region 
of TNFA or in the autoinflammatory TNFRSF1A and MEFV genes, concur with 
HLA-B27 in enhancing the risk of SpA and/or in predicting the response to anti-
TNFα treatment [63]. The results of this study indicate the relevant role of TNF-
TNFR pathway genetics in the complex network inducing SpA and conditioning 
response to therapy. TNFA was shown to be a predisposing factor for SpA, but 




mainly for AS, while the autoinflammatory gene MEFV appears of no impact in 
this setting. The haplotype resulting from TNFA-1031C/-308G, seems to exert a 
protective role in AS, while the TNFRSF1Ac.625+10A>G polymorphism appears 
as a potential predictor of response to anti TNF-α drugs. Other genes involving in 
the axSpA pathogenesis are, also, linked to the IL-17/IL-23 pathway, the activation 
of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signal, 
the antigen presentation and the immune T cells system activation (Figure 3). In 
literature are also been hypotized the role of genes encoding the IL-23 receptor (IL-
23R), prostaglandin E receptor 4 (PTGER4), Runt-related transcription factor 3 
(RUNX3) or Scr homology 2 adaptor protein 3 (SH2B3) [64]. While some specific 
haplotypes are strongly associated with an increased risk of AS, other variants 
appear to be AS protective [65]. Some data also suggest that ERAP1 inhibition 
could potentially be effective for clinical applications [66].   
Unlike other inflammatory rheumatic diseases such as rheumatoid arthritis (RA), 
the inflammatory process of axSpA predominantly involves the enthesis. Numerous 
recent studies have provided evidence regarding local inflammation of enthesis. 
From the last data in the pathogenesis of the SpA it was discovered how the 
primitive triggering event is considered the "stress of the enthesis". Biomechanical 
stress initiates enthesitis by triggering mechanoreceptors which induce an 
inﬂammatory response via the mitogen activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) pathway [67] and the 
prostaglandin release.  These prostaglandins seems to induce osteoblast activation 
through inhibition of sclerostin via the prostaglandin E4 receptor and consecutive 
ERK signaling [68]. It is been also indentified  the significantly presence of IL-
23R-positive T cell  in the enthesis  and in the subchondral bone marrow of 
neighboring joints parallel to the discovery of elevated concentrations of systemic 
IL-17 and IL-23  [69,70]. 
 
 





Figure 3. IL-17 secreting cells in inflammatory diseases and in axSpA. 
AHR, aryl hydrocarbon receptor; CCR6, CC chemokine receptor type 6; IL-23R, IL-23 
receptor; Lti,  lymphoid tissue inducer; NKG2D, natural killer cell receptor D; NKT, 
natural killer T (cell); NETosi (neutrophil extracellular traps), processo di formazione 
delle NET; RORγT, thymus-restricted RAR-related orphan receptor-γ; STAT-3, signal 
transducer and activator of transcription 3; TCR, T-cell receptor; Th17, type 17 T helper; 
TLR, Toll-like receptor. 
(Da Kenna TJ, Brown MA, Nat Rev Rheumatol, 2013; 9:375-79) 
 
Different cell types produce IL-17 in inflammatory diseases by induction by IL-23 and IL-
1β. Lymphocytes of innate immunity, such as Tγδ cells, NKT cells and LTi lymphocytes, 
and TCD4 + Th17 lymphocytes, constitute a relevant source of IL-17, and sometimes IL-
22, in the inflammatory process, as well as mast cells and polymorphonuclear cells. The 
stimulus capable of inducing IL-17 production by different cell types is still unclear. 
Sensitization to exogenous or commensal bacteria, activation of innate immunity receptors 
and reticular-endothelial stress caused by protein misfolding have been implicated in the 
pathogenetic mechanisms that can lead to the activation of these cells. 
Bone homeostasis in axSpA is unbalanced due to an excessive bone formation 
determining the squaring of the vertebral bodies possibly evolving toankylosis of 
the vertebral column on one side, due to an excessive bone resorption on the other 
side, the latter accompanied by a reduction in bone mineral density in the spinal 




vertebrae of axSpA patients and osteoporosis [71]. Wnt signaling seems to play an 
important role in osteogenesis with an increased differentiation and proliferation of 
osteoblasts, with the role of Dickkopf-1 (Dkk1) [72], the bone morphogenetic 
protein (BMP) [73] or other inﬂammatory molecules. Generally speaking then, 
entheseal and gut inﬂammation further enhances chronic inﬂammation, resulting in 
excessive bone formation and bone resorption of the spine, although the exact 
interplay between genetic predisposition, inﬂammation and disturbed bone 
homeostasis remains undeﬁned.  
Because of the absence of rheumatoid factor in axSpA, the disease is thought to be 
seronegative and antibodies are not considered one of its hallmarks. There is 
nevertheless increasing evidence that B cells and the humoral immune response 
play a role in axSpA [74]. After encountering an antigen, some of the B cells 
differentiate into antibody-producing plasma cells and plasmablasts found elevated 
in blood and joints of axSpA; the antibodies that bind to their antigen triggers the 
formation of immune complexes, which neutralizes foreign substances, inducing 
the macrophages to the phagocytosis or activing the complement pathway [75,76]. 
The exact mechanisms by which antibodies contribute to axSpA pathogenesis 
remain unelucidated, nevertheless it is seems antibody complexes could induce to 
osteoclast activity [77].  Besides antibodies, also cytokines such as the receptor 
activator of nuclear factor kappa-B ligand (RANKL), which has been found to be 
increased in AS patients, could mediate osteoclastogenesis [70,78,79]. Just as 
RANKL, serum levels of Interleukin 6 (IL-6) are also increased in AS patients [80]. 
Recently, anti-CD74 antibodies with speciﬁcity to a class II-associated invariant 
chain peptide (anti-CLIP-ABs) were found in axSpA patients [81]. Binding of CLIP 
antibodies to CD74 may lead to activation of cells and production of 
proinﬂammatory cytokines such as TNFα. Baraliakos et al. [82] found anti-CLIP-
Abs in 85.1% in axSpA but in only 7.8% in non-SpA patients, analyzing 
respectively 145 sera from 94 axSpA and 51 non-SpA patients. This result seems 
to substain the strong association of anti-CLIP-Abs with axSpA. Nevertheless, 
more studies are needed to establish its usefulness in clinical practice. A discordant 




result was obtained in other study conducted in early axSpA patients, participating 
in the SpondyloArthritis-Caught-Early (SPACE) prospective cohort study [83]: 
although anti-CD74 IgA levels have been found elevated in patients with early 
axSpA in previous investigations, in this study this finding appears not sufficiently 
specific to yield significant diagnostic value in patients suffering with inflammatory 
low back pain (LBP) (≥3 months, ≤2 years, onset < 45 years). An other interesting 
article examining the antibodies involved in axSpA and mainly in AS pathogenesis, 
instead demonstrated that these antibodies were detected in only a small number of 
axSpA patients and that they were also found in the sera of RA and other 
inflammatory arthropathies, thus limiting their specificity and their distinctive 
character as biomarkers for axSpA diagnosis [84]. 
1.2.2 THE ROLE OF SEROLOGICAL INFLAMMATORY AND BONE 
REMODELLING BIOMARKERS IN AXSPA 
The National Institute of Health Biomarkers and Surrogate Endpoint Working 
Group have elaborated the definition of biomarker as a “characteristic that can be 
objectively measured and evaluated as an indicator of normal biological or 
pathogenic processes or pharmacological responses to a therapeutic intervention” 
[85]. The importance of identifying new predictive biohumoral markers of disease 
activity and severity in order to detect and treat early axSpA has been highlighted. 
Unlike other inflammatory arthropathies, there are no specific biomarkers of 
disease activity in axSpA that are presently being used in clinical practice. Recent 
studies have focused on the role of some new markers to diagnose early axSpA, to 
assess disease activity, and to identify patients at higher risk for a worse outcome 
[86,87,88-90] (Figure 4). Serum and plasma biomarkers have recently undergone 
extensive examination since HLA-B27, the biomarker commonly used in 
spondyloarthropathies, and C-reactive protein (CRP) and the eritrocyte 
sedimentation rate (ESR), the inﬂammatory markers generally used in clinical 




practice to monitor systemic inflammation, are often unable to assess disease 
activity [91-94].  
 
 
Figure 4. Biomarkers and pathophysiology of axSpA.  
 Serum (Inflammation) markers: CRP, VEGF, TNF, IL-6, IL-12, IL-21, IL-22, IL-23, IL-33, MMP-
3, MMP-8, MMP-9, VICM, OPG, Aggregan, COMP, YKL-40, Calprotectin, SAA, CTLA-4; 
 Bone remodelling markers: CRP, VEGF, MMP-3, VICM, C2M and C3M, Dkk-1, OPG, BAP, 
Sclerostin, Osteocalcin, Fetuin-A, Cathepsin K. 
 
Legend: C-reactive protein (CRP); Serum amyloids A (SAA); Vascular endothelial growth factor 
(VEGF); Tumor necrosis factor (TNF); Interleukin 6 (IL-6); Interleukin 17 (IL-17); Interleukin 21 
(IL-21); Interleukin 22 (IL-22); Interleukin 23 (IL-23); Interleukin 33 (IL-33); Cytotoxic T 
lymphocyte associated molecule (CTLA-4); Matrix metalloproteinase 3 (MMP-3); Matrix 
metalloproteinase 8 (MMP-8); Matrix metalloproteinase 9 (MMP-9); Citrullinated fragments of 
vimentin (VICM); Circulating protein fragments of cartilage and connective tissue degradation 
Fig.4 
Fig.4 




(C2M and C3M); Cartilage oligomeric matrix protein (COMP); Osteoprotegerin (OPG); Bone 
alkaline phosphatase (BAP); Serum human cartilage glycoprotein-39 (YKL-40); C-terminal cross-
linking telopeptide of type I  (CTX-I) and type II (CTX-II) collagen; Wnt proteins and Dickkop-1 
(Dkk-1); Human leukocyte antigen (HLA)-B27; IL-23 receptor (IL-23R); prostaglandin E receptor 
4 (PTGER4); endoplasmic reticulum aminopeptidase 1 (ERAP1); Runt-related transcription factor 
3 (RUNX3);  Scr homology 2 adaptor protein 3 (SH2B3). 
 
The CRP and ESR, recognized as acute-phase proteins reflecting systemic 
inflammation, are commonly utilized in clinical practice [95], although they do not 
reflect completely the inflammation process in axSpA due to the low sensitivity and 
specificity [96].  An elevated CRP is one of the classification criteria of the 
Assessment of Spondyloarthritis International Society (ASAS) for axSpA, while 
CRP level is taken into consideration in the Ankylosing Spondylitis Disease Activity 
Score (ASDAS) and correlates with the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI) [97]. However, an elevated CRP or ESR is detected in 
only about 40–50 % of AS patients [98]. The degree of observed inflammation, in 
fact, fluctuates during the course of axSpA. In general, CRP level is higher in 
patients with radiographic axSpA with respect to nr-axSpA [99]. Although CRP is 
within the normal range in a large proportion of patients with active axSpA, it is 
still widely considered a reliable parameter of disease activity. In fact, CRP levels 
are moderately correlated with MRI inflammation [88,89,93,99]. In addition, CRP 
has been found to be a reliable biomarker for monitoring treatment response and 
predicting further radiographic progression. Several studies have demonstrated that 
CRP levels fall significantly during anti-TNFα treatment [89,91,93]. Modifications 
in CRP levels are correlated with changes in BASDAI and MRI scores, while 
elevated baseline CRP levels are associated with a good treatment response [91,93] 
and represent a strong positive predictor of radiographic sacroiliitis progression, in 
particular for the progression from nr-axSpA to AS [93]. Several prospective 
studies have also demonstrated that elevated CRP levels are independently 
associated with radiographic spinal progression in axSpA patients [100]. In 
summary, CRP currently appears to be a reliable biomarker for assessing disease 




activity and predicting structural progression and treatment response. ESR, instead, 
appears to be a non-specific measure of inflammation that may be influenced by a 
variety of other non-rheumatic conditions and comorbidities. However, some 
studies reported that higher ESR levels such as increased CRP levels are 
independently associated with structural disease progression in nr-axSpA patients 
[100].  
Studies on cytokines’ levels have produced variable results. The discovery of the 
involvement of TNFα in disease pathology led to the development of therapeutic 
antibodies targeting this cytokine. Considered a hallmark of the disease, TNFα has 
been for a long time the only cytokine known to be involved in axSpA pathogenesis. 
TNFα plays a key role in the pathogenesis of axSpA, providing a possible link 
between the inflammatory response and disturbed bone homeostasis [101], exerting 
several effector and biological functions via the pro-inflammatory cytokines and 
chemokine release, the activation of endothelial cells with up-regulation of adhesive 
molecules, the leucocyte accumulation, the angiogenesis, the lymphocyte 
activation, the fibroblast proliferation and the chondrocyte and osteoclast 
activation. TNFα levels are significantly higher in AS patients with respect to 
subjects with non-inflammatory back pain or healthy controls [101], and TNFα 
expression is strongly up-regulated in the SIJ biopsies of AS patients [102] 
Although TNFα is not a reliable biomarker of disease activity, the discovery of anti-
TNF α agents has been demonstrated an important pharmacological result in the 
axSpA treatment [103], and it has significantly improved the outcome of these 
patients.  According to the updated 2016 ASAS recommendations, axSpA patients 
who meet the ASAS classification criteria can be treated with anti-TNF α agents if 
a minimum of four weeks of first-line treatment with two non steroidal anti-
inflammatory drugs (NSAIDs) prove ineffective in reducing disease activity [103]. 
These biological agents are considered efficacious in preventing irreversible joint 
damage, ankylosis, impaired functionality, and work disability when prescribed at 
an early disease stage [104]. One of the most extensively studied cytokines, IL-6, 
is a classic proinflammatory cytokine produced by a variety of immune cells that 




stimulates the production of several acute phase proteins [101] and it is involved in 
the initial phases of multiple immune-mediate diseases. The IL-6 is involved in the 
first phases of the inflammation disease by inducing neutrophils’accumulation in 
the inflammation site and modulating T cell activation and differentiation. Some 
researchers have reported higher IL-6 serum levels in AS patients with respect to 
healthy controls [101,105]. Elevated IL-6 levels have been found in SIJ biopsies of 
AS patients, particularly in early stage [106]. While some studies have 
demonstrated associations between IL-6 levels and either disease activity or 
inflammatory markers [101,107,108], others did not confirm these results [88,109]. 
Normalization of IL-6 levels has also been reported in association with lower MRI 
inflammation scores [88]. Interleukin 17 (IL-17) and IL-23 are key cytokines in 
the Th17 pathway, and the IL-23/IL-17 immune axis appears to be a very important 
pathway in the pathogenesis of axSpA [110-112]. A number of studies reported 
elevated IL-17 and IL-23 levels in the plasma and serum of AS patients and 
associated them with disease activity [70,113,114]. The IL-17/IL-23 axis is also 
crucially involved in other inflammation and autoimmune diseases [115]. IL-17 is 
mainly produced by Th17+ T-helper cells under the stimul of the IL-23. The 
number of IL-17+T cells and the IL-17 serum levels in circulation is higher in AS 
patients with respect to healthy individuals and to subjects with degenerative 
changes [70,110,116-120]. Interestingly, the number of IL-17+T cells is increased 
in patients with early active axSpA [110].  However, in some studies, systemic IL-
17 levels correlated neither with inflammatory indices nor with clinical disease 
activity parameters [70,118]. The fact that TNFα agents could reduce the number 
of Th17 cells and serum IL-17 levels confirms the role of IL-17 axis in axSpA 
pathogenesis [118]. Just as IL-23 induces  IL-17 production, even IL-23 serum 
levels [110,114,119] and IL-23 expression in the subchondral bone marrow from 
the facet joints [70] are up-regulated in AS patients, but only a few studies have 
found a positive correlation between IL-23 serum levels and CRP values, MRI 
inﬂammation or clinical disease activity [114,118].  Both IL-17 and IL-23 levels 
signiﬁcantly fall in responders to anti-TNF α therapy while they rise in non-




responders [118]. Nowadays, both cytokines (IL-17, IL-23) have become important 
therapeutic targets [121-125]: clinical trials showed that ustekinumab, a 
monoclonal antibody against the p40 subunit shared by IL-12 and IL-23, and 
secukinumab, a monoclonal antibody against IL-17, produced clinical 
improvements in axSpA patients [121-125]. In addition to the above discussed 
cytokines, IL-21 and IL-22, both interconnected with IL-17 and Th17 cells, are 
elevated in AS patients [70, 126-128]. Interleukin 33 (IL-33), a member of the IL-
1 family, has recently been recognized its role in several inflammatory and 
autoimmune diseases.   Three independent centers in China [129-131] have reported 
elevated IL-33 serum levels in AS patients and found correlations with disease 
activity or other inflammatory markers. 
Matrix metalloproteinases (MMPs) (and in particular MMP-3) are zinc-dependent 
endopeptidases which are involved in the degradation of extracellular matrix 
proteins. These molecules, which also play a role in cell proliferation, migration, 
differentiation, angiogenesis, apoptosis and host defence, have been considered 
possible biomarkers of disease activity. MMP-3 serum levels are increased in AS 
patients with respect to healthy controls [132-134].   In fact, some investigators 
have reported that MMP-3 was correlated with CRP levels, disease activity and 
functional status, as assessed by the BASDAI and BASFI [89, 132, 135-138]. 
Another study reported a correlation between serum MMP-3 levels and BASDAI 
and ESR [88]. That study found that MMP-3 levels were significantly higher in 42 
AS patients with respect to 20 controls and were correlated with BASDAI and 
BASFI, supporting the hypothesis that MMP-3 is more reliable than ESR or CRP 
in assessing disease activity [88]. MMP-3 levels have even been found to be 
correlated with disease activity in PsA patients [138-140]. Maksymowych et al. 
reported that anti-TNFα treatment induced a significant decrease in serum MMP-3 
levels together with a reduction in conventional variables (ESR and BASDAI) 
[137]. Although serum MMP-3 represents a reliable parameter of disease activity, 
this has not always been reflected in MRI-documented studies examining 
inflammation of the SIJ [135]. According to a study by Van Kuijk et al. [141] 




evaluating 24 SpA patients who were randomized to receive adalimumab 40 mg 
once every 14 days or placebo, a reduction in serum MMP-3 levels was noted after 
only 4 weeks of anti-TNFα therapy, but no change was detected in serum levels in 
the placebo group. As this molecule is increased in active forms of SpA or in 
patients with important clinical involvement, this would support the hypothesis that 
MMP-3 reliably assesses disease activity. Maksymowych et al. showed that MMP-
3 was a significant independent predictor of radiographic progression over a two 
year observation period in 97 axSpA patients [136], suggesting that MMP-3 could 
be considered a parameter of bone metabolism.  Although fewer studies have been 
carried out on MMP-8 and MMP-9, they have been shown to be associated with 
disease activity, as assessed by the BASDAI score [142]. 
Citrullinated fragments of vimentin (VICM) are MMP-degraded fragments 
modiﬁed by citrullination, an unspeciﬁc modiﬁcation during the inﬂammatory 
phase [143]. VICM levels are signiﬁcantly higher in AS patients with respect to 
healthy controls. Bay-Jensen et al. [143] found that higher VICM levels and high 
baseline mSASSS values were associated to a worse risk of radiographic 
progression over a two year period.  
Osteoprotegerin (OPG), a member of the TNF receptor superfamily, has been 
shown to be involved in osteoclastogenesis by activating T cells through the OPG 
ligand (RANKL). According to some studies, OPG levels were lower in patients 
with AS, [144,145], while according to others they are higher [146,147]. OPG 
seems to correlate with BASDAI scores, but not with treatment response [146,147]. 
Serum human cartilage glycoprotein-39 (YKL-40), a secretory protein of human 
articular chondrocytes and synoviocytes, has been considered a marker of cartilage 
remodelling and associated with disease activity in AS [88]. YKL-40 levels are 
significantly higher in SpA patients with respect to healthy controls [105].   
The cartilage oligomeric matrix (COMP) protein catalyzes the assembly of 
collagen in the extracellular matrix. Although findings on its association with other 
clinical and disease activity markers in AS have been inconsistent, elevated COMP 
levels have been reported in a variety of inflammatory joint diseases [88]. One study 




nevertheless reported an inverse relationship between COMP levels and MRI 
inflammation in axSpA patients [89].  
Aggrecan is the central component of cartilage extra-cellular matrix. The 
replacement of the glycosaminoglycan side chain with aggrecan with charge 
density modification determines osmotic processes, fundamental for the 
biomechanical properties of cartilage. AxSpA patients have been found to have 
depressed levels of total aggrecan with respect to healthy subjects [88]. 
Calprotectin is a heterodimeric calcium- and zinc-binding protein complex, 
composed of S100A8 and S100A9 subunits, expressed in the cytosol of 
keratinocytes, neutrophils and monocytes. Hammer et al. found it to be a plasma 
marker of inflammation and treatment response in reactive arthritis and axSpA 
[148].  Higher calprotectin levels have been found in the SIJ of AS patients [147]. 
Some studies have reported that serum calprotectin levels are significantly higher 
in axSpA and that anti-TNFα treatment significantly reduces calprotectin levels 
[149,150]. Baseline calprotectin serum levels have been found significantly 
increased in patients with higher modified Stoke Ankylosing Spondylitis Spinal 
Scores (mSASSS) versus those without [151]. According to another study, a 
significant decrease in serum calprotectin was noted after intensive physiotherapy 
in both nr-axSpA and AS patients [152]. 
Serum amyloids A (SAA) proteins are a family of apolipoproteins associated with 
high-density (HDL) lipoproteins that are produced as a response to an inflammatory 
trigger. AS patients have higher serum SAA levels with respect to healthy controls; 
those levels were also correlated with other inflammatory and disease activity 
parameters [153,154]. 
Cytotoxic T lymphocyte associated molecule (CTLA-4) is an inhibitor molecule of 
immune response. One study demonstrated higher CTLA-4 serum levels in axSpA 
patients with respect to healthy controls. It also appears a marker of disease activity 
due to correlation with CRP and BASDAI [155]. 
Vascular endothelial growth factor (VEGF) is a molecule inducing angiogenesis, 
an inflammatoryinitial phase in the remodelling bone process with the new bone 




formation. VEGF serum levels appeared higher in AS and axSpA patients 
[88,156,157], expecially in those with active disease [156] and with a worse 
radiographic progression according to mSASSS. 
Type I and type II collagen are proteins of cartilage and components of connective 
tissue. Some studies reported that variations in radiographic progression were 
correlated to both type I and II C-terminal telopeptides (CTX-I and CTX-II), other 
studies demonstrated the role of only CTX-II levels [157,158]. It has been shown 
that urinary CTX-II levels are higher in AS patients with respect to those in healthy 
controls [159]. CTX-II was also found to be correlated with other serological 
inflammation markers [157,160]. According to another study, it has been found a 
correlation between higher baseline CTX-II levels and higher pre-treatment MRI 
inflammation scores for SIJ and/or lumbar spine in axSpA patients. [89]. Anti TNFα 
treatment contributed to significantly reduce urinary CTX-II levels, that correlated 
with improvement in disease activity [160]. CTX-II also appears to be a biomarker 
of radiographic progression in axSpA. Higher CTX-II levels have been found in AS 
patients with worse radiographic spinal progression respect to those without 
[157,159]. In some studies in AS patientes higher levels of two neo-epitope 
biomarkers have been demonstrated: C2M, a serum biomarker that measures a 
matrix metalloproteinase (MMP)-generated neo-epitope of type II collagen, and 
C3M, a biomarker of soft tissue turnover associated with inflammation [143,161]. 
One study used therefore a combination of C2M and C3M, dichotomized according 
to the best cut offs for individual markers, as predictor index of radiographic 
progression. CTX-I is a marker of osteoclast activity reﬂecting bone degradation 
[162]. Both urinary and serum CTX-I levels are higher in AS patients with respect 
to those in healthy controls [159,163].  
Sclerostin (SOST) and noggin (NOG) are bone morphogenic protein (BMP) 
antagonists. Findings reported by studies focusing on sclerostin levels in AS 
patients have not always been consistent. One German study reported that both 
sclerostin expression in osteocytes from AS patients measured  using 
immunohistochemical techniques and both sclerostin serum levels were 




significantly lower (with respect to that in osteocytes and blood of healthy 
individuals and RA patients)[164]. Importantly, that study reported that low serum 
sclerostin levels in AS patients were significantly associated with new 
syndesmophytes formation. Similar findings were reported in axSpA [147] and in 
a Brazilian cohort of AS patients [165]. 
Wnt proteins are extracellular signaling molecules. There are at least two families 
of secreted inhibitors of Wnt signaling: the secreted frizzled-related transmembrane 
receptors with N-terminal cysteine-rich domain and the Dickkopf proteins, which 
includes Dkk1. In several studies AS patients with no syndesmophyte formation 
have been shown to have significantly higher Dkk1 levels. This result seem to 
suggest that blunted Wnt signaling suppresses new bone formation and 
consequently syndesmophyte growth and spinal ankylosis [166,167], although no 
modifications were found after anti-TNF-α treatment [168].  In contrast with other 
studies [169,170], lower levels were reported in the AS patients with respect to 
those in the healthy subjects.  
Osteocalcin is a small molecule of the mineralized bone matrix. Initial studies have 
shown that osteocalcin levels are lower [171], but more recent studies have reported 
higher levels in AS patients with respect to those in controls, especially in those 
individuals who later developed new syndesmophytes [93, 170]. 
Bone-specific alkaline phosphatase (BAP) is a marker of active bone formation. 
Higher levels of BAP have been reported in patients with axSpA [158, 164, 166]. 
The fetuin family encompasses a series of proteins that have been implicated in 
several biological functions involving in both inflammatory stage (regulation of 
insulin and hepatocyte growth factor receptors and acute phase proteins) and bone 
remodelling phase (osteogenesis and bone resorption).  AS patients with 
syndesmophytes have been shown to have significantly higher levels of fetuin-A 
with respect to patients without syndesmophytes and to healthy controls [172]. 
The cathepsin K, which is a highly potent collagenase predominantly expressed in 
osteoclasts, is involved in bone remodelling and resorption; its expression is 
stimulated by inﬂammatory cytokines that are released after tissue injury. There are 




actually discordant results about the cathepsin K levels in AS: some studies reported 
higher expression of cathepsin K in mononuclear cells, ﬁbroblast-like cells, and 
cells attached to bone but similar systemic levels to those in healthy controls [173, 
174]. Some studies reported higher adipokines levels, in particular leptin values, in 
some rhematological diseases [175,176]. In AS patients with structural bone 
damage and syndesmophytes were found higher adiponectin levels [176]. The 
results so far obtained are discordant; other studies have demonstrated lower or 
similar leptin levels in AS patients respect to healthy subjects [177]. 
 
 
1.3 THE EVALUATION WITH IMAGING OF THE AXIAL 
SPONDYLOARTHRITIS 
 
1.3.1 THE ROLE OF THE STANDARD RADIOGRAPHIC EXAM 
In the diagnosis of axSpA a relevant role is played by the radiographic exam, which 
is also useful for monitoring the progression of bone lesions. We can distinguish 
initial, late and advanced signs. On pelvis X-rays a symmetrical or asymmetric 
sacroiliitis, which is classified in grades (I-II-III-IV) according to the severity of the 
radiological damage, can be recognized. The earliest detectable lesion in the SIJ at 
the standard radiograph is an initial disruption of the cortical margin of the 
subchondral bone, with initial involvement of the third lower segment of the joint, 
followed secondarly by erosions and sclerosis. The evolution of erosion produces a 
false enlargement of the joint spaces. When fibrosis and ankylosis occur, the SIJ 
appear to be obliterated until complete fusion (Images 3 a-d, see iconography). The 
spinal lesions are initially characterized by a straightening of the column (Figure 
4, see iconography). There may also be an osteitis in the vertebral bodies which 
causes a "square" alteration of the vertebral bodies ("squaring") which may result 
in erosion (sign of "Romanus") (Images 5-6, see iconography). The progressive 
ossification of the fibrous ring of the intervertebral disc induces the formation of 
marginal syndesmophytes, detectable radiographically in the anterior and lateral 




views, which connect the vertebral bodies to each other; the syndesmphytes are 
typical osteoproductive aspects that may be found in the axSpA (Images 7-9, see 
iconography). With the passage of time, the calcifications and ossifications involve 
the entire spine, sometimes leading to bone flows, involving the anterior 
longitudinal ligament (sign of the "bamboo cane") or of the inter-apophyseal joints 
(sign of the "track") or inter-spinous ligaments (sign of the "dagger") or all these 
structures together (sign of the "cog railway") (Images 10 a-b, see iconography). 
Sometimes, the osteoproductive process derived from the inflammatory 
involvement of the spinal enthesis determines the formation of non-marginal 
calcific bridges (pseudo-syndesmophytes) which are generally monolateral and 
asymmetric (especially found in the form of axial psoriatic spondyloarthritis). The 
osteoproductive processes with the formation of calcifications can also be observed 
in the periphery, especially in shoulders, hips and heels. In the established disease 
phase, traditional radiographs are largely sufficient to clarify the clinical picture. 
The three main radiological scoring methods used for the spine are BASRI (Bath 
Ankylosing Spondylitis Radiology Index), SASSS (Stoke Ankylosing Spondylitis 
Spine Score), mSASSS (modified Stoke Ankylosing Spondylitis Spine Score) [178-
181 (Table VII). The mSASSS method appeared to be the most appropriate method 
for assessing and monitoring the development of syndesmophytes and the 
radiographic progression. In a recent study the SASSS and BASRI methods were 
found to have good reproducibility, but both showed a low sensitivity to detect 
change [182]. Furthermore, the mSASSS method was more reliable than the 
remaining two methods in quantifying the score of structural spinal lesions [183]. 
These methods have been performed and adopted in clinical trials in order to 
evaluate the therapeutic response of anti-TNFα agents and non-steroidal 









Table VII. Radiological scoring methods for radiographic axSpA or AS 
 
 
BASRI-spine (range 2-12) (for the lumbar spine, AP and lateral views are analyzed, and 
the projection with the highest score is considered; for the cervical spine, the lateral view 
is analyzed) 
0 = normal (no alteration) 
1 = suspicious or mild (initial alteration not well defined) 
2 = average (some erosions, squaring, or sclerosis, with or without syndesmophytes, visible 
on ≤ 2 vertebrae) 
3 = moderate (syndesmophytes on ≥3 vertebrae, with or without fusion involving ≥2 
vertebrae) 
4 = severe (fusion involving ≥3 vertebrae) 
 
Modified SASSS (range 0-72) (anterior corners of the lumbar spine and anterior corners 
of the cervical spine from the inferior margin of C2 to the upper margin of T1 analyzed on 
the lateral view) 
0 = normal 
1 = erosion, sclerosis, or squaring 
2 = syndesmophytes 
3 = bone bridges with fusion 
 
New York criteria for sacroiliitis (range 0-4) (mean score of both SIJ is used in BASRI) 
0 = normal 
1 = suspicious or mild (initial alteration not well defined) 
2 = minimum (minimum sacroiliitis, defined as the loss of definition of the SIJ rhyme, mild 
juxta-articular sclerosis, minimal erosions and the presence of a slight reduction of joint 
space) 
3 = moderate (moderate sacroiliitis, defined as marked sclerosis on both sites, thickened 
and indistinct margins of SIJ and erosive lesions, with loss of joint space) 
4 = severe (complete fusion or ankylosis of SIJ) 
 
SIJ: sacroiliac joint; BASES: Bath Ankylosing Spondylitis Radiology Index; AP: anterior-
posterior; SASSS: Stoke Ankylosing Spondylitis Spine Score 
 


















1.3.2 THE ROLE OF THE MAGNETIC RESONANCE IMAGING  
The MRI has revolutionized the diagnosis and the concept of the SpA. Some recent 
studies [36-38, 191-193] have shown the superiority of MRI compared to other 
methods in the search of recent onset lesions. This method appears to be able to 
define inflammatory lesions in the active phase. It is both sensitive and very specific 
in demonstrating lesions in the articular cartilage, the synovium and the 
subchondral bone. Its ability to detect such alterations is of considerable help in the 
diagnosis of early disease forms, when no alterations or erosions or other structural 
lesions are detected, and allows early therapy to be undertaken [42, 194-197]. The 
diagnosis of axSpA is currently based on the presence of inflammatory and / or 
structural lesions in the SIJ and in the spine. The appearance of inflammatory signs 
in progress or previous is crucial for the possibility of early recognition of the 
transition from non-radiological forms of axSpA to the AS. 
Two sequences in MRI are used, both of which can detect both inflammatory and 
structural lesions. The weighted spin-echo T1 (T1SE), with relaxation time in which 
the water shows an hypointense signal, is mainly used for the identification of 
structural alterations, such as chronic osteitis, erosions, ossification and sclerosis; 
the STIR (Short-Tau-Inversion-Recovery), a sequence able to differentiate the 
water signal from that of fat and to obtain the saturation of fat (FS) in T1, is 
preferable for the study and visualization of inflammatory lesions, characterized by 
an important liquid and vascular component, such as BME and synovitis. BME, 
characterized by the increase in the STIR signal, represents the main alteration 
induced by inflammatory activity in the axSpA and is highlighted early on the SIJ 
by the MRI (Images 11-12, see iconography). Among the structural lesions, 
erosions are the most specific for axSpA, and are well highlighted by the sequences 
T1SE as interruptions of the cortical bone, with altered signal in the subchondral 
bone (Images 13-14, see iconography). At spine MRI the BME of the vertebral 
anterior corners (anterior osteitis) and the posterior corners (posterior spondylitis) 
appears as hyperintense area in the STIR sequence; the spondylodiscitis appears as 
hyperintense region in the STIR and hypo-intense sequence in T1SE (Images 15-




21, see iconography). Adipose metaplasia appears as a hyperintense area in the 
same sequences. The ossification of vertebral enthesies (syndesmophytes) appears 
as hypointense areas near the cortical bone, and when they are not associated with 
adipose metaplasia, they are more difficult to identify in MRI because they could 
be confused with the peri and para-vertebral ligaments that appear as ipo-intense 
areas. A set of MRI-ASAS criteria is currently underway for the definition of the 
MRI imaging pattern specific for the classification of axSpA forms [191, 192, 36-
38, 46], where both inflammatory and structural alterations are considered, 
expression of inflammatory activity or of chronic pathological process, different 
phases of the natural course of SpA (Table VIII). Based on the definition of the 
ASAS / OMERACT criteria, SIJ MRI is considered positive if ≥1 highly suggestive 
inflammatory lesion (BME) per SpA is present on ≥2 consecutive slices or if ≥2 
inflammatory bone lesions are visible on a single slice [ 191, 37]. The presence of 
synovitis, enthesitis or capsulitis alone, unaccompanied by BME, is not sufficient 
to consider a SIJ MRI as positive. According to the ASAS criteria, the spondylitis 
is confirmed by the signs of BME, anterior or posterior, in ≥3 vertebrae, or of 
adipose metaplasia located in several vertebral bodies [198-201]. Less specific to 
SpA are spondylodiscitis or flogistic involvement of the inter-apophyseal joints 
[202]. This definition is still very preliminary and only the application on large 
series will allow to classify and distinguish more precisely the aspects of 
degenerative nature and those derived from the inflammatory process that can be 
seen at the MRI. As for conventional radiology, also different methods of 
evaluation of acute and chronic lesions have been proposed both for the spinal and 
SIJ MRI [203-205]. Recently it has been proposed a scoring method for the 
evaluation of acute and chronic spinal lesions, with score between 0-6 (activity 
score: ASspiMRI-a and chronicity score: ASspiMRI-c), and for SIJ lesions, with 
score ranging 0-3 for acute lesions and 0-5 levels for chronic lesions [206,207]. The 
second method for the evaluation of acute lesions (BME) detectable in spine and 
pelvis MRI, is the one recently proposed and validated by the Canadian research 




group for SpA, defined as Spondyloarthritis Research Consortium Canada 
(SPARCC) magnetic resonance imaging index [43,44]. 
 
Table VIII) Definition of MRI imaging according to ASAS 
__________________________________________________________________ 
 
 for the positivity of sacroiliitis: 
o presence of active inflammatory lesions:: 
 bone oedema in STIR* or osteitis inT1-FS-Gd*, with typical 
appearance and localized in specific anatomical sites (i.e. 
subchondral or periarticular bone marrow).  
 synovitis, enthesitis or active capsulitis, without the previous ones 
is not considered sufficient  
o presence of structural lesions: 
  adipose metaplasia, sclerosis, erosions or ankylosis reflect 
previous inflammation, but are not sufficient in the absence of 
inflammatory lesions 





 for the positivity of spondylitis: 
o presence of active inflammatory lesions: 
 anterior and posterior spondylitis (inflammatory lesions at 
vertebral corners) are typical lesions of the axSpA, when present 
in at least three sites 
 spondylodiscitis (inflammatory lesions of the vertebral plates) are 
considered less specific  
 lesions of the interapophyseal and costovertebral joints are 
specific, but less standardized  
o presence of structural lesions: 
 adipose metaplasia, sclerosis, erosions or ankylosis, with 
localization in multiple sites, particularly in younger subjects with 
axSpA. 
 erosions, syndesmophytes and ankylosis, are not yet standardized 
 
*Short-Tau-Inversion-Recovery sequence 
* T1-wighted fat saturated post-Gadolinium sequence 
__________________________________________________________________ 
Pedersen Susanne J. Ulrich Weber b, MikkelØstergaard Best Practice & Research Clinical 








PURPOSE OF THE THESIS 
AxSpA which mainly affects the spine and the SIJ, has an early onset at a young 
age and can be further subdivided between nr-axSpA and radiographic axSpA, the 
latter also known as AS [31]. If undiagnosed and untreated, axSpA may lead to 
permanent damage and lifelong disability [31,32,103]. Significant steps forward 
have been taken in the management of axSpA in clinical practice after the discovery 
and spread of the use of anti-tumor necrosis factor α (TNFα) drugs. It has been 
demonstrated that axSpA patients respond quickly to anti-TNFα drugs, which 
appear to be very effective. Therefore, identifying early stages of these disorders 
could be a benefit for patients, whom could be prescribed appropriate treatment 
[2,3]. The Assessment of SpondyloArthritis International Society (ASAS) has 
established classification criteria to identify patients with early stages of axSpA 
[31]; the imaging arm of the criteria requires the presence of sacroiliitis on magnetic 
resonance imaging (MRI) or radiographs in addition to one SpA feature for patients 
with chronic low back pain with onset at age ≤45 years. Conventional radiographs 
of SIJ, which are still frequently used to detect sacroiliitis, do not appear to provide 
adequate information to classify patients with suspected early axSpA [9]. This is 
due to the fact that they are able to detect only structural damage, which is indicative 
of a more advanced disease stage [9,31]. Hence, MRI constitutes an important 
additional screening option since it can detect inflammatory lesions of SIJ in 
patients with early-onset axSpA without evidence of radiographic sacroiliitis, and 
thus before bone damage begins to be visible [35]; in spite of this, MRI is often 
prescribed only to confirm a rheumatologist’s suspicion of axSpA as it is an 
expensive, relatively time-consuming test, which is not readily available at all 
health care centers [35]. Positive SIJ MRI scans were defined by the 
ASAS/Outcome Measures in Rheumatology MRI working group 
(ASAS/OMERACT) as the presence of inflammatory lesions such as BME which 
is highly suggestive of SpA [35]. Whether structural SIJ lesions should be added to 
this definition and if structural and inflammatory spinal lesions could contribute to 




detecting axSpA remains to be established [36]. Inflammatory spinal lesions on 
MRIs may nevertheless occur in the absence of SIJ involvement [192]. Spinal MRIs 
in AS patients have uncovered abnormalities in this district even before they are 
noted on plain radiographs [45]. The introduction of fat-suppression sequences has 
allowed the visualization of lesions within bone marrow that may be obscured on 
MRI by marrow fat. These lesions include BME adjacent to vertebral endplates at 
the attachment of the annulus fibrosus to the vertebral rim and at the insertion of 
anterior and posterior longitudinal ligaments, both within the facet joints. Since 
there is evidence that spondylitis may also occur prior to or even without sacroiliitis, 
it was considered important to define the characteristics of a spinal MRI considered 
positive for inflammation. The ASAS/OMERACT working group thus set out to 
define spinal MRIs positive for inflammatory lesions (spondylitis) and structural 
changes (fat deposition) [36]. It is also unknown whether the localization of lesions 
is correlated to the site of axial pain. Imaging of the thoracic spine, which is often 
involved in axSpA, has not yet been taken into consideration when structural 
damage is being evaluated [180-182]. Since patients usually display a wide variety 
of clinical features and there is no standardized laboratory test protocol, a diagnosis 
of axSpA is rarely straightforward. As a result of the growing awareness of the 
impact of chronic back pain in axSpA patients, and in view of recent breakthroughs 
in genetics research and the development of novel treatments with a potentially 
positive impact on early disease stages, recent studies have been focusing on the 
use of MRI and the role of new biomarkers that could facilitate early diagnosis and 
identify those individuals at higher risk for poor prognosis [86-89]. As early 
treatment can reduce the disease burden of axSpA patients and disease-related 
costs, uncovering biomarkers that can facilitate early diagnosis of axSpA has 
become an urgent undertaking.  
The our aims are the following: 
1) To evaluate patients with early low back pain (> 3 months and ≤ 2 years) 
and to study whether patients presenting with back pain of short duration 
can be diagnosed as early axial SpA according to ASAS classification 





2) Evaluate the predictive parameters for the diagnosis of early axSpA and the 
role of imaging methods (standard plain radiography and MRI of the spine 
and of the pelvis) in the diagnostic process in the forms with or without SIJ 
involvement; 
3) To study the additional value information of imaging (plain radiography and 
MRI) to the other parameters in making a diagnosis of SpA; 
4) To define the characteristics and prevalence of inflammatory and structural 
on MRI of the spine and of the pelvis in patients with early axSpA; 
5) To investigate how MRI features evolve over time and how they relate to 
radiographic damage; 
6) To evaluate if the localization of axial pain correlates with the site of the 
inflammatory and structural lesions on MRI; 
7) To analyze the correlation of radiographic and MRI lesions with the clinical, 
serological, functional and disease activity indices; 
8) To evaluate the expression of some serological biomarkers (hsCRP, ESR, 
MMP3, IL-17, IL-22, IL-23) as possible predictive indicators of severity 
and / or disease activity or as possible indicators of bone remodeling in 
patients with axSpA; 
9) To evaluate the biomarkers in relation to the different axial involvement 
(presence or absence of sacroiliitis) and to other clinical, functional and 
disease activity indices; 
10) To identify the subset of patients with a more active and severe disease 
pattern and with a higher probability of radiological progression with severe 
structural bone damage; 
11)  To evaluate the response to early treatment in terms of change of clinical, 
serological, functional, disease activity indices in patients with low back 
pain for a follow-up of 24 months. 
 




MATERIALS AND METHODS 
 
Patients who were at least 16 years old, suffering by inflammatory low back pain 
(LBP) (≥3 months, ≤2 years, onset < 45 years) of unknown origin and referred to a 
rheumatologist were included in this on-going observational cohort study. Eligible 
patients underwent physical examinations, laboratory tests, following a 
standardized protocol at baseline (T0), at 6 months (T6), at 12 months (T12) and 24 
months (T24). The patients also completed questionnaires on disease activity, 
physical functioning, pain, and disease-related impairment. SIJ and spinal plain 
radiographs and MRIs were performed at T0 and once year. Axial pain and MRI 
lesions were localized in 4 sites: in the cervical/thoracic/lumbar spine and the SIJ. 
Two experienced rheumatologist formed the diagnosis of axSpA according ASAS 
2009 criteria [31]. In order to meet the ASAS criteria [31], it was necessary to verify 
if the patients had MRI evidence of active inflammatory lesions of the SIJ with 
definite BME which is highly suggestive of sacroiliitis. After the X-rays and MRI 
images were read, the patients were divided into three cohorts: those fulfilled the 
imaging arm of ASAS axSpA criteria (axSpA imaging arm+), those fulfilled the 
clinical arm of ASAS axSpA criteria (axSpA clinical arm+) and those not fulfilled 
completely ASAS axSpA criteria (not full ASAS axSpA).  
The local medical ethical committee approved the study and informed consent was 
obtained from all patients at study inclusion. 
 
PATIENTS 
1. Subject selection 
1.1. Inclusion criteria  
 Male and female patients of at least 18 years 
 Chronic back pain of at least 3 months with a maximum duration of 2 years 
with onset before the age of 45 years  
 An increased risk for axSpA. This can be achieved by the following 
combination of features in addition to the chronic back pain. 
At least one of the following features: 




• HLA-B7 pos  
• positive family history 
• acute anterior uveitis  
• inflammatory and or structural changes on the MRI of SIJ 
• radiographic sacroiliitis according to the modified New York criteria  
OR at least two of the following features:  
• Inflammatory back pain (defined as at least 3 out of the following 4: age at  
            onset< 40 years, insidious onset, morning stiffness and improving with  
            exercise) 
• Heel pain typical for enthesitis 
• Peripheral arthritis  
• Dactylitis 
• Psoriasis  
• IBD 
• Good response to NSAIDs 
• Elevated ESR and/or CRP 
 Written informed consent 
 
1.2 Exclusion criteria  
 Patients with back pain for more than 2 years 
 Patients with a painful condition not related to axSpA, which could interfere 
with the evaluation of disease activity i.e. Paget disease. 
 Intake of conventional synthetic Disease-Modifying Anti-Rheumatic Drugs 
(csDMARDS) and biological Disease-Modifying Anti-Rheumatic Drugs 
(bDMARDS) already at the recruitment visit 
 A history of alcoholism, drug abuse, psychological or other emotional 
problems, severe co-morbidity that are likely to invalidate informed consent 




Baseline, after T6, T12, and T24 for all patients, followed by annual visits for 











1. Physician clinical assessments: 
a) collection of anamnestic information, related to age, sex, characteristics of 
chronic inflammatory low back pain, duration and onset of axial pain, type of joint 
involvement (axial and / or peripheral), presence of other articular and extra-
articular manifestations, presence or familiarity for arthritis and / or psoriasis, 
association with other rheumatological and / or non-rheumatological diseases, 
previous or current pharmacological therapy at the time of the visit; 
b) Overall assessment of disease activity by the physician on an 10-point 
numerical rating scale (NRS) (0=inactive disease with no symptoms and 
11=extremely active disease). The physician should consider all clinical 
information in assessing the patient’s disease activity on the day of the visit; 
c) Number of tender joints of a total 61 joints be examined. The following joints 
are examined by pressure for tenderness: temporo-mandibular joint (R+L), 
sternoclavicular joint (R+L), acromioclavicular joint (R+L), shoulder (R+L), elbow 
(R+L), wrist (R+L), 10 MCPs, 8 PIPs, 2 IPs of the thumb, 8 DIPs, knee (R+L), 
ankle (R+L), subtalar joint (R+L), midtarsal (R+L), 10 MTPs. Pain on motion will 
be examined for cervical spine and hip (R+L); 
d) Number of swollen joints of a total 52 joints be examined. The following joints 
are examined for presence of swelling: sternoclavicular joint (R+L), 
acromioclavicular joint (R+L), shoulder (R+L), elbow (R+L), wrist (R+L), 10 
MCPs, 8 PIPs, 2 IP of the thumb, 8 DIPs, knee (R+L), ankle (R+L), 10 MTPs; 
e) Chest expansion: it should be measured as the difference in centimetres to the 
nearest 0.1 cm between full expiration and full inspiration, measured at the fourth 
intercostals space. The better of two tries should be recorded; 
f) The Bath Ankylosing Spondylitis Metrology Index (BASMI): composite index 
formed by the set of results of cervical rotation, occipital-to-wall distance, modified 
Schober test, lateral flexion, intermalleolar distance (score 0-10). Occiput-to-wall 
test: heels and, if possible, the back against the wall, with the distance measured in 




centimetres to the nearest 0.1 cm from the occiput to the wall during maximal effort 
to touch the head to the wall, without raising the chin above its usually carrying 
level. The better of two tries should be recorded. Modified Schober test: it is 
performed by marking a point over the spinous process of L5 (found as the first 
process below the projected line across the back at the level of the top of the iliac 
crest, although the exact point is not absolutely critical). The second point is 
measured 10 cm directly above the first while the patient is extending his lumbar 
spine in a neutral position. The patient then flexes forward as far as possible and 
the (now longer) distance between the two points is measured. Normally the initial 
10 cm distance increases to 16 cm or more. The actual distance in centimetres 
measured in full flexion should be recorded. Cervical rotation: it is measured with 
a gravity action goniometer. The patient lies supine in the neutral position and the 
goniometer is placed centrally on the forehead. The patient is then asked to turn the 
head as far as possible to the right and then to the left. The better of two tries is 
recorded for left and right. The mean of left and right gives the final result for 
cervical rotation (in degrees). Lateral spinal flexion: it is measured by fingertip to 
floor distance in full lateral flexion without flexing forward or bending the knees. 
The patient should stand as close to the wall as possible with shoulders level. The 
distance between patient’s middle fingertip and the floor is measured with a tape 
measure. The patient is asked to bend sideways without bending his knees or lifting 
his heels and attempting to keep his shoulders in the same place. A second reading 
is taken and the difference between the two is recorded. The better of two tries is 
recorded for left and right. The mean of left and right gives the final result for lateral 
spinal flexion (in cm). Intermalleolar distance: it is measured with the patient 
supine, the knees straight and the feet pointing straight up. The patient is asked to 
separate the legs as far as possible and the distance between the medial malleoli is 
measured (in cm to the nearest cm). The better of two tries should be recorded; 
g) The Maastricht Ankylosing enthesitis Spondilities Score (MASES):  Enthesis 
index score that measures the number of painful enthesis to pressure (0-13). 
 




2. Patient assessments: 
a) Pain of the spine (Visual Analogical Scale Back Pain- VAS back pain):  this 
will be assessed by the patient on a 11-point numerical rating scale (NRS) where 0 
at the left end of the scale is no pain and 10 is unbearable pain. The following 
question will be asked: “How severe was the pain of your spine on average during 
the last week?”; 
b) Patient assessment of disease activity (Visual Analogical Scale Disease 
Activity- VAS disease activity): this will be assessed by the patient by on a 11-point 
numerical rating scale (NRS) where 0 at the left end is inactive disease with no 
symptoms and 10 is extremely active disease. The following question will be asked: 
“How active was your disease on average last week?”; 
c) Severity of night pain (Visual Analogical Scale Night Pain- VAS night pain):  
this will be assessed by the patient by on a 11-point numerical rating scale (NRS) 
where 0 at the left end is inactive disease with no pain and 10 is unbearable pain. 
The following question will be asked: “How much pain due to your disease did you 
have at night on average last week?”; 
d) the Bath Ankylosing Spondylitis Patient Global Score (BASG1), as an 
assessment of the influence of disease activity on the state of health in the last week 
on a numerical scale from 0 to 10; 
e) BASG2 (evaluation of the influence of disease activity on the state of health in 
the last six months on a numerical scale from 0 to 10); 
f) BASFI (Bath Ankylosing Spondylitis Functional Index): validated composite 
questionnaire composed of 10 questions concerning the functional abilities of the 
patient, whose answers will be evaluated using the numerical scale NRS; 
g) HAQ (Health Assessment Quality): questionnaire comprising 20 questions 
concerning activities of daily life and subdivided into 8 categories (the sum of the 
scores between 0-24 and divided by 8 gives the final score). 
 
3. Disease activity assessments: a) the Ankylosing Spondylitis Disease Activity 
Score (ASDAS), a composite index comprising both subjective measures and 




laboratory parameters (back pain-pain of the peripheral joints-duration of morning 
stiffness-VAS disease activity-CRP); b) BASDAI (Bath Ankylosing Spondylitis 
Disease Activity Index): validated composite questionnaire composed of 6 
questions concerning the activity of the disease, the answers of which will be 
evaluated using the numerical scale NRS. 
 
4.Biochemical assessments: 
Biochemical parameters include the erythrocyte sedimentation rate (ESR) 
(Westergren method in mm after 1 hour; normal range 0-15 mm/h) and C reactive 
protein (CRP) [normal range 0-6 mg/L] and Serum ultrasensitive C reactive protein 
(hsCRP, ELISA in mg/l; Research & Diagnostic Systems, Inc., expressed in mg/L, 
with a lower limit of detection of 0 mg/L). The following serological markers were 
assessed: matrix metalloproteinase MMP3, (Quantikine MMP3 R&D Systems 
Europe, expressed in ng/mL, with a lower limit of detection of 0 ng/mL); interleukin 
IL-22, IL-17 and IL-23 (R&D Systems Europe, expressed in pg/mL, with lower 
limit of detection respectively of 5 pg / mL, 17 pg / ml, of 20 pg/mL) using an 
enzyme-linked immunosorbent assay (ELISA). Bank serum, plasma, urine will be 
stored at -70C.  DNA will also be collected. Serum for the assays was separated by 
centrifugation at 3000 rpm for 10 minute. All blood samples were analyzed twice 
using the same method.   
 
5. Radiological assessments: 
 
MRI assessments. 
SIJ and spinal MRIs were performed at baseline using a 1.5 T scanner Magnetom 
Harmony, Siemens AG Medical Solutions, Munich, with phased-array surphace 
coil, acquiring T1-weighted turbo spin echo (T1TSE; TR 550/TE 10) and short-tau 
inversion recovery (STIR; TR 2500/TE60) sequences. The coronal oblique and 
sagittal views of the SIJ and spine were taken, with a slice thicknessof 4 mm. The 
images were independently analyzed by two expert radiologists trained in MRI 




scoring  according to the ASAS/OMERACT [36] definition and the SPARCC 
scoring system [43,44] for both SIJ and the spine. If the two readers scored positive, 
the image was scored accordingly. All readers were blinded for clinical and 
laboratory data, and for the results of the other imaging methods. The mean scores 
were calculated using those of both of the readers. Intra and inter-observer 
reliability was calculated.   
SIJ MRIs were graded using the SPARCC scoring system for the inflammatory 
lesions typical of SpA: MRI is graded positive if ≥1 BME lesion highly suggestive 
of SpA is visible on ≥2 consecutive slices or if several BME lesions highly 
suggestive of SpA are visible on a single slice [35]. The presence of only synovitis, 
enthesitis, or capsulitis without BME is not sufficient for a positive reading. 
According to the SPARCC scoring method, the presence of an increased signal 
corresponding to BME lesions on SIJ-MRIs should be assessed on 6 consecutive 
coronal slices selected as representing the synovial compartment of the SIJ. The left 
and right SIJ MRIs were divided into quadrants for a total of 8 per coronal slice. 
Each quadrant was assessed and evaluated for the presence (scored 1) or absence 
(scored 0) of BME. Each coronal slice per SIJ was given an additional score of 1 
for the presence of an “intense” signal and an additional score of 1 for a “deep” 
lesion, defined as a homogeneous, unequivocal increase in a signal 1 cm from the 
articular surface. The maximum possible score across 6 slices was 48 for the 
presence of BME, 12 for intense edema, and 12 for deep edema, for a maximum 
possible total score of 72 [43]. The presence of structural lesions on SIJ-MRIs were 
also evaluated.  
With regard to MRI of the spine, according to the ASAS/OMERACT MRI group, 
BME and fatty lesions on spinal MRIs are present when they are visible on ≥2 
consecutive slices, while the presence of ≥1 slice is enough for structural lesions 
(erosions, sindesmophytes) [36]. For the spine, the 6 most severely affected disco-
vertebral units (DVUs) were selected and each was divided into 4 quadrants, with 
each quadrant assessed for the presence (scored 1) or absence (scored 0) of BME. 
Each quadrant was scored on 3 consecutive sagittal slices per disco-vertebral unit 




(DVU), yielding a maximum possible score of 12 per DVU for BME. Each sagittal 
slice per DVU was given an additional score of 1 for the presence of an “intense” 
signal and an additional score of 1 for a “deep” lesion, defined as a homogeneous, 
unequivocal increase in STIR signal > 1 cm from the vertebral end plate. The 
maximum possible score for all 6 DVUs was 72 for the presence of BME, 18 for 
intense edema, and 18 for deep edema, for a maximum possible total score of 108 
[44]. Structural lesions on spinal MRIs were also evaluated. 
 
Radiographs assessments. 
Lateral view radiographs of the cervical and lumbar spine and anterior-posterior 
view radiographs of the pelvis were taken. The images were obtained with a Philips 
vertical bucky, with a focus-film distance of 140 cm, film size of 18x43 cm. The 
images were read independently by two expert trained musculoskeletal radiologists, 
blinded for patients characteristics, clinical outcome and for the results of the other 
imaging methods. The mean scores were calculated using those of both of the 
readers. It was performed intra and inter-observer reliability.  The mSASSS scoring 
method modified by Creemers was used [180]. According to this method, lateral 
views of the anterior vertebral corners (VCs) of the cervical (lower border of C2 to 
upper border of T1) and lumbar (lower border of T12 to upper border of S1) 
segments (a total of 24 VCs) are scored for the presence of erosions and/or sclerosis 
and/or squaring (1 point), syndemophyte (2 points) and bridging syndesmophytes 
(3 points). The total score ranges from 0 to 72 [180]. Evaluation of the SIJ was 
based on the New York criteria [9], with scores ranging from 0 to 4 (0=no change, 
1=look slightly faded edge joint, pseudo-widening or narrowing of the rhyme, mild 
subchondral sclerosis, 2=irregular margin joint with images of erosion, shrinkage 
of rhyme, subchondral sclerosis evident, 3=erosions and subchondral sclerosis 









At T0 all the patients were being treated with non-steroidal anti-inflammatory 
drugs. All patients will be treated according to the physician assessments and the 
severity of the disease if the latter is diagnosed. There is no limitation on 
pharmacological treatments, physical therapies or other treatments. 
 
STATISTICAL ANALYSIS 
The statistics used mainly descriptive methods. Odds ratio was used to evaluate the 
correlation between localization of the axial pain and the position of inflammatory 
and structural lesions on the spinal and SIJ MRIs at the baseline evaluation (T0). 
The Cohen's Kappa test was used to assess the intra and inter-observational 
reliability of the two radiologists' evaluations. Since the variables examined are not 
normally distributed, the differences between the values of the T0, T6, T12 and T24 
indices were evaluated using the Kruskal-Wallis nonparametric test for repeated 
measurements followed by the Dunn's multiple Comparison test. These tests were 
therefore used to compare the clinical (BASMI, MASES), bioumoral,serological 
(ESR, CRP, hsCRP, MMP3, IL-22, IL-17, IL-23), functional (BASFI, HAQ, 
BASG1, BASG2 , VAS back pain, VAS night pain, VAS disease activity) 
anddisease activity indices (BASDAI, ASDAS) at T0, T6, T12 and T24. The same 
method was used to compare the imaging scores (mSASSS, score SI mNY, 
SPARCC-SIJ and SPARCC-spine) at T0 and T24 in all patients and  among the 
three cohorts (axSpA imaging arm +, axSpA clinical arm + and not full ASAS 
axSpA). A T0 regression analysis was performed to identify the predictors of 
inflammationand radiological progression of the disease evaluated using mSASSS, 
score SI mNY, SPARCC- SIJ and SPARCC-spine indices. The following 
independent variables were considered in the univariate analysis: female sex, age 
of CBP onset, duration of CBP, presence of HLA-B27, elevated inflammation 
indices, BASDAI>4, use of NSAIDs. The significant independent variables (p<0.1) 
in the univariable analysis were tested using multivariable regression models. 
Interactions and correlations between the variables were analyzed using the 




Spearman correlation coefficient. The radiographic progression of SIJ from T0 to 
T24 was evaluated (defined according to the criteria formulated by DESIR study 
[208]: 1- passage from the non-radiographic form to the radiographic stage of 
sacroiliitis according to the mNY criteria; 2- change of> 1 degree of sacroiliitis but 
ignoring the passage from degree 0 to 1 of sacroiliitis), using the non-parametric 
Kruskal-Wallis test. The radiographic progression of the spine from T0 to T24 was 
evaluated according to the method provided by Poddubnyy tested in the GESPIC 
cohort [209] (increase in mSASSS score> 2 over the course of 2 years of 
observation). All statistical analyzes were performed using the SPSS 13.0 program 























In this study, 75 patients diagnosed with axSpA were enrolled. According to the 
ASAS criteria for axSpA; 21 (28%) patients were classified as axSpA imaging 
arm+, 29 (38.7%) patients as axSpA clinical arm+ and 25 (33.3%) patients did not 
full ASAS criteria for axSpA. The average age at back pain onset was 28.51 ± 8.05 
years, 45.3% were male, 38.7% had HLA-B27+. 52% (39) of patients presented an 
exclusive axial involvement, while 48% (36) of patients also had peripheral 
involvement. A high prevalence of psoriasis and heel enthesitis was observed 
(33.3% and 72%, respectively). Other characteristics of the patients, including the 
typical aspects for SpA, have been reported in Table IX. Out of all 75 patients, 
37.3%, 56%, 100% and 64%, respectively, complained of cervical / thoracic / 
lumbar / buttock pain. The clinical (MASES and BASMI), disease activity 
(BASDAI, ASDAS), functional (HAQ, BASFI, VAS back pain, VAS pain night, 
VAS disease activity, BASG1, BASG2) and serological indices (ESR, CRP, 
hsCRP, MMP3, IL17, IL22, IL23) were analyzed and measured over time at T0, 
T6, T12 and T24. Out of all 75 patients, 68 (90.7%) were evaluated at T6, of 

















Table IX:  Baseline characteristics of  patients with LBP (n=75) 
Age of onset LBP, mean (±SD) 28.51 (±8.05) 
Male, n (%) 34 (45.3%) 
Duration (months) di LBP, mean (±SD) 13.37 (±6.14) 
Only axial involvement, n (%) 39 (52%) 
Axial and peripheral involvment, n(%) 36 (48%) 
HLA-B27 positive, n (%) 29 (38.7%) 
Positive family history of SpA, n (%) 35 (46.7%) 
IBP, n (%) 75 (100%) 
Peripheral arthritis, n (%) 34 (45.3%) 
Psoriasis, n (%) 25 (33.3%) 
Dactylitis, n (%) 15 (20%) 
Heel enthesitis, n (%) 54 (72%) 
Uveitis, n (%) 7 (9.3%) 
IBD, n (%) 9 (12%) 
Preceding infections, n (%)† 4 (5.3%) 
Good response to NSAIDs, n (%) 73 (97.3%) 
Elevated CRP/ESR, n (%) 42 (56%) 
Cervical pain, n (%) 28 (37.3%) 
Thoracic pain, n(%) 42 (56%) 
Buttock pain, n (%) 48 (64%) 
Alternating buttock pain, n (%) 37 (49.3%) 
Morning stiffness, n (%) 57 (76%) 
Night pain, n(%) 71 (94.7%) 
Sacroiliitis MRI *, n (%) 46 (61.3%) 
Sacroiliitis x-ray **, n (%) 25 (33.3%) 
Weight (kg), mean (±SD) 70.22 (16.15) 
Height (cm), mean (±SD) 170.6 (8.67) 
HLA-B27, Human Leukocyte Antigen; LBP, low back pain; IBP, Inflammatory Back Pain; IBD 
Inflammatory Bowel Disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MRI, 
Magnetic Resonance Imaging; SpA, Spondyloarthritis; NSAID, nonsteroidal antiinflammatory drugs 
* Sacroiliitis on MRI according ASAS/EULAR criteria 
** Sacroiliitis on X-Rays according modified New York criteria (0-4) 










a) The prevalence of the inflammatory and structural lesions on pelvis and spine 
MRI in patients with LBP at T0. 
All spine and SIJ on MRI images were evaluated by two expert readers and the 
inter-observer reliability was good to moderate (kappa 0.73 for inflammatory 
lesions and 0.60 for structural lesions on spine MRI;kappa 0.78 for inflammatory 
lesions and 0.61 for structural lesions on SIJ MRI respectively). The inter-observer 
reliability for all X rays images was good (kappa 0.79 for spine radiological lesions 
and kappa 0.77 for SIJ radiological lesions). The intra-observer reliability was good 
for all spine and SIJ images on X-rays and MRI (respectively kappa 0.79 for spine 
and 0.83 for SIJ).  Fifty-two (69.3%) patients presented structural and/or 
inflammatory lesions on SIJ-MRIs at T0 (on the right SIJ in 63% of the patients and 
on left one in 59% of the patients). BME lesions were present in 46 (61.3%) patients 
(58% on the right SIJ and 50% on the left one). Structural lesions on SIJ-MRI were 
present in 33 (44%) patients (37% on the right SIJ and 30% on the left one). Fifty 
(66.7%) patients presented inflammatory and/or structural lesions on the spinal 
MRI at T0. BME lesions at the anterior corner of the spine were present in 42 (56%) 
patients (19%, 39% and 33%, respectively, in the cervical/thoracic/lumbar regions). 
Structural spine lesions were present in 28 (37.3%) patients (18%, 14%, 19%, in 
the cervical/thoracic/lumbar regions respectively,) (see Figures 5a-b). Signs of 
enthesitis were found in 47 (62.7%) patients: at the level of the cervical spine in 8% 
of patients, of the thoracic spine in 58% of patients, at the lumbar spine in 11% of 
patients. At T0 18 (8 patients of axSpA clinical arm+ cohort and 10 patients of not 
full ASAS axSpA cohort) patients with inflammatory lesions on spinal MRIs 
showed no abnormalities in SIJ, while 11 (14.7%) patients without active sacroiliitis 
on SIJ MRIs did not present spine MRIs lesions (Table X). 
 




            
 
            
 
Figures 5 a-b: Prevalence in percentage (%) of MRI lesions for single articular 
district at T0. 
 
 
Table X: Prevalence of inflammatory (BME) lesions on MRI at T0, T12 and 
T24. 
 
INFLAMMATORY LESIONS (BME) T0 T12 T24 
MRI SPINE +/ MRI SIJ + 29 (38.7%) 24 (40.7%) 26 (48.1%) 
MRI SPINE +/ MRI SIJ- 18 (24%) 13 (22.1%) 5 (9.3%) 
MRI SPINE -/ MRI SIJ + 17 (22.7%) 12 (20.3%) 9 (16.7%) 
MRI SPINE -/ MRI SIJ - 11 (14.7%) 10 (16.9%) 14 (25.9%) 










b) Association between localization of axial pain and the site of BME and 
structural lesions at MRI at T0. 
The OR between the pain site and the corresponding localization of BME lesions 
were 20.78 (CI: 0.39-11.05; p=NS), 163.93 (CI: 3.31-81.28; p=0.0006); 0.34 (CI: 
0.01-17.91; p=NS) for cervical / thoracic / lumbar spine and 304.88 (CI: 1.71-
546.56; p=0.0203) for SIJ. Pain was not significantly associated with structural 
lesions on MRI at the same site, except for the correlation between buttock pain and 
structural lesions on SIJ MRI (OR=70.1, CI: 0.84-58.40; p=0.0122). Moreover, the 
association between the axial pain site and the localization of enthesitis evaluated 
by OR showed a significant association between thoracic pain and enthesitis of the 
thoracic district (OR=32.69; CI: 1.096-9.748; p=0.0336). 
 
c) The prevalence and the charateristics of MRI lesions in the three cohorts at T0 
and T24. 
The prevalence of inflammatory and structural MRI lesions at T0 in the three 
cohorts (axSpA imaging arm+, axSpA clinical arm+ and not full ASAS axSpA) 
is outlined in Table XI. As it could be expected, an increased prevalence of 
structural lesions on SIJ MRI was found in the axSpA imaging arm+ patients with 
respect to the other two cohorts in accordance with a greater presence of sacroiliitis 
involvement on standard X-rays in this cohort. AxSpA imaging arm+ and axSpA 
clinical arm+ patients had more inflammatory and structural spinal lesions with 














Table XI. The prevalence of inflammatory and structural lesions at T0 and 
T24 in three cohorts (axSpA imaging arm +, axSpA clinical arm +, not full 
ASAS axSpA). 
 
  T0  MRI evaluation    
  
axSpA imaging arm+ axSpA clinical arm+ Not full ASAS axSpA 
Total number of patients 21 (28%) 29 (38.7%) 25 (33.3%) 
SIJ total lesions 21 (100%) 27 (93.1%)  4 (16%) 
BMO lesions 21 (100%) 25 (86.2%)  0 (0%) 
sclerosis lesions 10 (47.6%) 14 (48.28%) 0 (0%) 
fatty lesions 7 (33.3%) 2 (6.9%) 4 (16%) 
erosions lesions 8 (38.1%) 3 (10.3%) 0 (0%) 
        
Spine total lesions 20 (95.2%) 19 (65.5%) 11 (44%) 
BMO lesions 18 (85.7%) 15 (51.7%) 9 (36%) 
enthesitis lesions 17 (80.9%) 19 (65.5%) 11 (44%) 
fatty lesions 6 (28.6%) 7 (24.1%) 4 (16%) 
sclerosis/syndesmophytes lesions 6 (28.6%) 6 (20.7%) 3 (12%) 
erosions lesions 2 (9.5%) 2 (6.9%) 1 (4%) 
  T24 MRI evaluation    
  
axSpA imaging arm+ axSpA clinical arm+ Not full ASAS axSpA 
Total number of patients 16 (29.6%) 22 (40.7%) 16 (29.6%) 
SIJ total lesions 16 (100%) 15 (68.2%) 1 (6.3%) 
BMO lesions 9 (56.3%) 13 (59.1%) 0 (0%) 
sclerosis lesions 7 (43.8%) 10 (45.5%) 0 (0%) 
fatty lesions 6 (37.5%) 4 (18.2%) 1 (6.3%) 
erosions lesions 3 (18.8%) 2 (9.1%) 0 (0%) 
        
Spine total lesions 11 (68.8%) 4 (18.2%) 7 (43.8%) 
BMO lesions 7 (43.8%) 5 (22.7%) 5 (31.3%) 
enthesitis lesions 7 (43.8%) 6 (27.3%) 7 (43.8%) 
fatty lesions 6 (37.5%) 4 (18.2%) 4 (25%) 
sclerosis/syndesmophytes lesions 7 (43.8%) 3 (13.6%) 2 (12.5%) 









d) Correlation analysis using Spearman tests between clinical, serological, 
disease activity indices and radiological scores in 75 patients with LBP at T0. 
Spearman analysis was conducted at T0 across all parameters and as expected, 
significant correlations were found among the clinical indices (BASFI, BASG1, 
BASG2, VAS) and between clinical and disease activity indices (BASDAI, 
ASDAS) (data not shown). The correlations between the clinical indices, MMP3 
and IL-22 are reported in Table XII, while in Table XIII correlations between ESR 
and hsCRP and clinical indices are shown. Of these, the most significant are also 
represented in the figures (Figures 6 a-f). 
 
       Table XII: Correlations between MMP-3, IL-22 and clinical indices and imaging  
       scores. 
     
 MMP3 IL-22 
ESR 0.047 ns 
hsCRP 0.026 ns 
mSASSS 0.005 ns 
SPARCC-SIJ ns 0.046 
BASMI ns 0.038 
BASFI ns 0.008 
BASG1 ns 0.008 
HAQ ns 0.041 
MMP3 ns 0.017 
P was calculated according Spearman’s correlation test. The coefficient is positive unless 
otherwise stated.  
 
Table XIII. Correlations between hsCRP, ESR and clinical indices and 
imaging scores. 
 
 hsCRP ESR 
BASG1 ns 0.027 
BASG2 ns 0.044 
ASDAS ns 0.025 
SPARCC-SIJ 0.043 ns 
mSASSS ns 0.033 
P was calculated according Spearman’s correlation test. The coefficient is positive unless 
otherwise stated.  
 




          
 
          
 
          
Figure 6 a-f: Spearman test: p<0.05 
     
        Legend 
        Correlations between serological, clinical and disease activity indices in patients with early axSpA at  
        baseline according to the Spearman correlation test (p<0.05) 
(a) mSASSS and MMP3; (b) IL-22 and BASFI; (c) IL-22 and BASG1; (d) IL-22 and HAQ; (e) 
IL-22 and VAS pain; (f) MMP3 and CRP. 
         ESR, erytrocyte sedimentation rate; CRP, C-reactive protein; MMP3 matrix-metallo-proteinase 3; IL,    
         Interleukine; BASFI: Bath  Ankylosing Spondylitis Functional Index, HAQ: Health Assessment  
         Questionnaire; BASG1,Bath Ankylosing Spondylitis Patient Global Score 1; VAS, Visual Analogue  













e) Analysis using Kruskal-Wallis test of clinical, serological, disease activity, 
imaging indices in total patients and in the following 3 cohorts (axSpA imaging 
arm+, axSpA clinical arm+, not full ASAS axSpA) at T0, T6, T12 and T24. 
Table XIV shows all the disease activity indices and imaging scores of the all 
patients and the three cohorts at T0. Using the Kruskal-Wallis test, a significant 
difference was observed between the three cohorts with regard to the percentage of 
radiographic sacroiliitis, of sacroiliitis at MRI and of radiographic SIJ scores 
according to the mNY and SPARCC-SI score criteria, but not as for the remaining 
clinical, functional, disease activity and serological parameters. In Tables XV and 
XVI the indices (values expressed as mean and standard deviation-SD) are reported 
for both total patients and the 3 cohorts (at T0, T6, T12 and T24), analyzed by 
Kruskal-Wallis test. Considering the total 75 patients, the comparison between the 
various timepoint highlighted a significant decrease of the following parameters 
values from T0 to T24: MASES (p=0.008), BASG1 (p=0.02), BASG2 (p<0.0001), 
HAQ (p=0.0002), VASpain (p=0.01), VAS pain night (p=0.04), VAS disease 
activity (p=0.05), BASFI  (p=0.02), ESR (p=0.04), BASDAI (p<0.0001), ASDAS 
(p<0.0001). On the other hand, BASMI and CRP did not decrease significantly. 
There were no differences in the serological markers (ILs, MMP3 and hsCRP) 
values during the 2 years follow up period in the three groups. The values of disease 
activity parameters (ASDAS and BASDAI) are also shown in Figures 7 a, b. 
Consideringthe patients subdivided in the 3 cohortsa downward trend for all 
functional indices (HAQ, BASFI, BASG1, BASG2, VAS back pain, VAS night 
pain and VAS disease activity) and disease activity indices (BASDAI, ASDAS) 
could be observed, which in some cases was statistically significant (see Table XV 
and Table XVI), but there was no more markedly significant decrease of these 








Table XIV: Serological, clinical, disease activity and imaging score indices at T0 
in the whole group of patients (n=75) and in the three cohorts (axSpA Imaging 
Arm+, axSpA Clinical Arm+, not full ASAS axSpA). 
 
Serological, clinical, disease activity 
and imaging score indices 
 Cohort 1  axSpA 
Imaging Arm +,   
          n=21 
Cohort 2 axSpA 
Clinical Arm +,  
        n=29 
Cohort 3 not full 
ASAS axSpA,  
         n=25 
p§ total=75 pts 
ESR (mm/h), mean (SD) 17.52 (12.98) 15.14 (11.76) 21.68 (21.19)   ns 17.99 (15.85) 
CRP (mg/L), mean (SD) 4.81 (3.61) 3.17 (3.32) 4.24 (3.28) ns 3.98 (3.42) 
hs-CRP (mg/L), mean (SD) 2.54 (2.79) 1.56 (1.71) 2.76 (3.76) ns 2.11 (2.50) 
MMP3 (ng/L), mean (SD) 3.04 (2.69) 3.51 (3.12) 2.47 (2.68) ns 3.01 (2.80) 
IL-22 (pg/mL), mean (SD) 6.44 (3.52) 5.91 (2.45) 9.83 (8.54) ns 12.58 (11.69) 
IL-17 (pg/mL), mean (SD) 3 (3.12) 3 (3.11) 3 (3.97) ns 3 (4.11) 
IL-23 (pg/mL), mean (SD) 29.3 (31.2) 21.87 (5.21) 20.69 (21.56) ns 71.53 (60.56) 
HLA-B27, n (%) 0 (0) 29 (38.7%) 0 (0) ns 29 (38.7) 
BASMI, mean (SD) 1 (1.18) 0.76 (1.02) 0.92 (1.08) ns 0.88 (1.08) 
MASES, mean (SD) 3.33 (2.65) 3.41 (2.35) 3.56 (2.47) ns 3.44 (2.45) 
BASFI, mean (SD) 17.43 (20.21) 13.68 (15.14) 22.44 (25.75) ns 17.65 (20.64) 
HAQ, media (DS) 0.34 (0.53) 0.30 (0.38) 0.52 (0.55) ns 0.39 (0.49) 
BASG1, media (DS) 3.43 (2.79) 3.52 (2.77) 4.64 (3.35) ns 3.87 (2.99) 
BASG2, media (DS) 5.71 (3.02) 5.10 (2.77) 5.28 (2.94) ns 5.33 (2.87) 
VAS pain, mean (SD) 3.48 (2.82) 4.10 (2.97) 5.08 (3.23) ns 4.25 (3.05) 
VAS disease activity, mean (SD) 3.81 (3.03) 4.07 (3.15) 5.04 (3.35) ns 4.32 (2.18) 
VAS pain night, mean (SD) 3.24 (3.33) 4.17 (3.57) 4.20 (3.33) ns 3.92 (3.40) 
BASDAI, mean (SD) 39.50 (25.99) 44.27 (25.03) 53.48 (24.97) ns 46.01 (25.07) 
ASDAS, mean (SD) 2.29 (0.86) 2.61 (0.56) 2.66 (0.88) ns 2.54 (0.77) 
Sacroiliitis x-ray **, n(%) 11 (52.4) 14 (48.3) 0 (0) <0.001 25 (33.3) 
Sacroiilitis MRI *, n(%) 21 (100) 25 (86.2%) 0 (0) <0.001 46 (61.3) 
mSASSS, mean (SD) 3.57 (4.25) 2.14 (2.84) 2.48 (3.82) ns 2.65 (3.61) 
score SIJ mNY*, mean (SD) 0.61 (0.67) 0.79 (0.98) 0 (0) <0.01 0.55 (0.78) 
SPARCC-spine, mean (SD) 6.52 (14.28) 6.45 (10.98) 2.32 (4.31) ns 5.09 (10.52) 
SPARCC-SIJ, mean (SD) 12.95 (8.23) 14.45 (15.11) 0 (0) <0.001 9.21 (12.28) 
 
ESR, erytrocyte sedimentation rate; CRP, C-reactive protein; hs-CRP, high sensitive C-reactive 
protein; MMP3 matrix-metallo-proteinase 3; IL, Interleukine; HLA-B27, Human Leukocyte 
Antigen; BASMI, Bath Ankylosing Score Metrology Index; MASES, Maastricht Ankylosing 
Spondilities Enthesitis Score; BASFI: Bath  Ankylosing Spondylitis Functional Index, HAQ: Health 
Assessment Questionnaire; BASG1,Bath Ankylosing Spondylitis Patient Global Score 1; BASG2, 
Bath Ankylosing Spondylitis Patient Global Score 2;BASDAI: Bath Ankylosing Spondylitis 
Disease Activity Index, VAS, Visual Analogue Scale; ASDAS, Ankylosing Spondylitis Disease 
Activity Score; SPARCC, Spondyloarthritis Research Consortium of Canada; mSASSS, 
modifiedStokeAnkylosingSpondylitis Spine Score, SIJ, sacroiliac joints. 
* Sacroiilitis MRI according ASAS/EULAR;  ** Sacroiliitis x-ray according New York criteria;  p§ 
Anova (Kruskal Wallis) a t0: p<0.05; SD=deviation standard. 




Table XV: Clinical and functional indices values from T0 to T24 in the whole group 
of patients (n=75) and in three cohorts (axSpA Imaging Arm+, axSpA Clinical 
Arm+, not full ASAS axSpA). 
 
 
Data are expressed as mean ± SD. The test Kruskal Wallis repeated measures test and Dunn's 
multiple comparison test were used  * p<0.0001 vs t0, **p<0.001 vs T0, ***p<0.01 vs t0.   
BASMI, Bath Ankylosing Score Metrology Index; MASES, Maastricht Ankylosing Spondilities 
Enthesitis Score; BASFI, Bath  Ankylosing Spondylitis Functional Index; HAQ: Health Assessment 
Questionnaire; BASG1,Bath Ankylosing Spondylitis Patient Global Score 1; BASG2, Bath 
Ankylosing Spondylitis Patient Global Score 2; VAS pain, Visual Analogue Scale pain; VAS dis 




















Table XVI: Serological and disease activity indices values from T0 to T24 in the 
whole group of patients (n=75) and in three cohorts (axSpA Imaging Arm+, 
























Data are expressed as mean ± SD. The test Kruskal Wallis repeated measures test and Dunn's 
multiple comparison test were used  * p<0.0001 vs t0, **p<0.001 vs T0, ***p<0.01 vs t0.   
ESR, erytrocyte sedimentation rate; CRP, C-reactive protein; hs-CRP, high sensitive C-reactive 
protein; MMP3 matrix-metallo-proteinase 3; IL, Interleukine; BASDAI: Bath Ankylosing 
Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score.  
                                         
                                 
 
Figures 7a-7b. P calculated according to the test Kruskal -Wallis.  
ASDAS, Ankylosing Spondylitis Disease Activity Score. BASDAI: Bath Ankylosing 
Spondylitis Disease Activity Index.         
P <0.0001
P <0.0001 




f) Regression analysis to identify the predictors of disease activity and 
radiological progression evaluated by mSASSS, score SIJ mNY, SPARCC-SIJ 
and SPARCC-spine scores at T0. 
At T0 a regression analysis was performed to identify any predictors of radiological 
activity on MRI (measured by continuous variables such as SPARCC-SIJ and 
SPARCC-spine) and of radiological progression (measured by continuous variables 
such as mSASSS and SIJ mNY score and dichotomous variables such as 
presence/absence of structural lesions on X rays of SIJ and spine). The following 
independent variables of activity and radiological progression were considered in 
the analysis: female sex, age of LBP onset, duration of LBP, presence of HLA-B27, 
increased inflammation indices, BASDAI> 4, use of NSAIDs. As it can be seen in 
the results reported in Tables from XVII to XXI, the multivariate analysis allowed 
to identify as possible independent predictors of radiological progression measured 
in the presence of structural lesions to the column: an early onset of IBP onset, a 
lower use of NSAIDs, a BASDAI>4. For the radiological progression measured by 
the presence of structural SIJ lesions, the only independent predictor was a high 
SPARCC SIJ score. An higher mSASSS score was independently predicted by a 
lower age of onset of IBP at multivariate analysis. Predictive factors of increased 
radiological activity were, respectively, for a higher SPARCC-spine score, a higher 
use of NSAIDs and for a higher SPARCC-SIJ score, the presence of HLA-B27 and 


















Table XVII. Predictors factors of mSASSS score at T0 
Independent Variables Univariate analysis Multivariable analysis 
  coeff (IC) p coeff (IC) p 
Female sex -0.80 (-2.55, 0.93) 0.359 - - 
LBP onset age 0.21 (0.11, 0.30) 0.000 0.19 (0.09, 0.29) 0.000 
Duration of LBP 0.02 (-0.12, 0.16) 0.770 - - 
HLA-B27+ -0.72 (-2.5, 1.08) 0.428 - - 
Increased ESR/CRP 0.97 (-0.80, 2.75) 0.278 - - 
BASDAI>=4 -0.48 (-2.22, 1.26) 0.583 - - 
Use of NSAIDs 2.63 (-0.22, 5.48) 0.070 1.22 (-1.46,  3.90) 0.367 
 
 
Table XVIII. Predictors factors of SPARCC-spine score at T0. 
Independent Variables Univariate analysis Multivariable analysis 
  coeff (IC) p coeff (IC) p 
Female sex -0.14 (-0.56, 0.28) 0.511 - - 
LBP onset age -0.01 (-0.04 , 0.00) 0.152 -0.02 (-0.05, 0.00) 0.124 
Duration of LBP 0.02 (-0.01, 0.05) 0.154 0.02 (-0.01, 0.05) 0.192 
HLA-B27+ 0.35 (-0.06, 0.78) 0.099 0.12 (-0.33, 0.58) 0.582 
Increased ESR/CRP 0.11 (-0.31, 0.54) 0.583 - - 
BASDAI>=4 -0.39(-0.81, 0.01) 0.058 -0.33 (-.73,  0 .07) 0.104 
Use of NSAIDs 0.60 (-0.26, 1.48) 0.168 0.88 (0.01, 1.75) 0.046 
 
 
Table XIX. Predictors factors of SPARCC-SIJ score at T0 
Independent Variables Univariate analysis Multivariable analysis 
  coeff (IC) p coeff (IC) p 
Female sex -3.59 (-9.54, 2.36) 0.233 - - 
LBP onset age -0.36 (-0.72, -0.004) 0.047 -0.25 (-0.60, 0.08) 0.140 
Duration of LBP 0.00 (-0.48, 0.49) 0.980 - - 
HLA-B27+ 9.41 (3.64, 15.18) 0.002 8.87 (3.08, 14.65) 0.003 
Increased ESR/CRP 4.46 (-1.59, 10.51) 0.146 5.74 (0.15, 11.34) 0.044 
BASDAI>=4 -3.94(-9.85, 1.96) 0.187 -3.14 (-8.55, 2.26) 0.250 











Table XX. Predictors factors of spine structural lesions (presence=1; 
absence=0) at T0 
Independent Variables Univariate analysis Multivariable analysis 
  RRR (IC) p coeff (IC) p 
Female sex 0.93 (0.69,  1.26) 0.661 - - 
LBP onset age 0.90 (0.84,  0.97) 0.006 0.89 (0.82, 0.97) 0.010 
Duration of LBP 0.97 (0.90,  1.05) 0.495 - - 
HLA-B27+ 1.22 (0.48, 3.08) 0.672 - - 
Increased ESR/CRP 0.46 (0.16,  1.31) 0.147 0.57 (0.16,  1.93) 0.369 
BASDAI>=4 2.15 (0.79,  5.85) 0.131 4.05 (1.15, 14.24) 0.029 
Use of NSAIDs 0.07 (0.008, 0.65) 0.019 0.09 (0.008, 0.99) 0.049 
 
 
Table XXI. Predictors factors of pelvis structural lesions (presence=1; 
absence=0) at T0 
Independent Variables Univariate analysis Multivariable analysis 
  RRR (IC) p coeff (IC) p 
Female sex 0.45 (0.17, 1.18) 0.107 0.65 (0.21,  2.01) 0.462 
LBP onset age 0.98 (0.92, 1.03) 0.527 - - 
Duration of LBP 1.00 (0.92,  1.08) 0.951 - - 
HLA-B27+ 1.45 (0.58, 3.60) 0.423 - - 
Increased ESR/CRP 1.27 (0.48, 3.35) 0.629 - - 
BASDAI>=4 0.43 (0.16, 1.14) 0.091 0.60 (0.19, 1.84) 0.375 
Use of NSAIDs 1.77 (0.32,  9.84) 0.511 - - 
SPARCC SIJ 1.07 (1.026,  1.13) 0.003 1.07 (1.01, 1.12) 0.007 
 
 
g) Evaluation of the radiographic progression of SIJ and of the spine from T0 
to T24. 
The radiographic progression of SIJ defined according to the criteria formulated by 
the DESIR study [208] was evaluated. In our population there was no significant 
radiographic progression of SIJ from T0 to T24. The radiographic progression of 
the spine was also evaluated according to the method provided by Poddubnyy tested 
in the GESPIC cohort [209]. In our study there was no a significant radiological 











Diagnosis and follow up of axSpA is still difficult to define, especially in early 
forms and in those associated to comorbidities or other manifestations belonging to  
SpA itself (psoriasis, inflammatory bowel disease or reactive arthritis) or to 
fibromyalgia. The use of SIJ and spine imaging in the diagnosis, classification and 
monitoring of axSpA is of considerable help. The standard radiography of the pelvis 
is currently used to determine structural changes and bone alterations, expression 
of a well-established and advanced pathological process, such as the sacroiliitis in 
AS. For the diagnosis of AS, radiographic sacroiliitis has played a role of 
considerable importance for a long time and has therefore been included among the 
classification criteria of New York (1984) [9]. In the last two decades, with the 
advent and development of new imaging methods, the interest to diagnose AS and 
axSpA forms atearlier stages, before structural damage has occurred, has grown, in 
order to establish an as earlier and more effective treatment as possible 
[29,31,32,210]. The MRI, due to the peculiar property of visualizing inflammatory 
lesions affecting the spine and SIJ, has been widely used in clinical practice and is 
increasingly requested and used in the process of diagnosing the patient with a 
history of chronic inflammatory low back pain, with suspicion of axSpA [35,36,38]. 
Thanks to the ability to guarantee a multiplanar vision, this method offers the great 
advantage of both identifying early inflammatory lesions (bone marrow edema) and 
simultaneously studying all the joint structures, including the bone, the synovial 
membrane, the tendons and ligaments, cartilage and periarticular soft tissues, thus 
allowing visualization of structural lesions [42,99,194]. A recent systematic review 
of the literature, conducted with the purpose of formulating the imaging criteria for 
the classification of axSpA [35], has highlighted the usefulness of the SIJ MRI in 
the diagnostic procedure of the SpA, trying to define the aspects on MRI that can 
be considered positive. Based on the definition of the ASAS / OMERACT criteria, 
a SIJ MRI is considered positive if at least one bone inflammatory lesion (BME), 




highly suggestive for SpA, is present on at least two consecutive slices or if at least 
two bone inflammatory lesions are visible on a single slice [37,81,191]. The 
presence of synovitis, enthesitis or capsulitis alone, unaccompanied by BME, is not 
sufficient to consider a SIJ MRI as positive. Recently, some studies [36,38] have 
also considered inflammatory and structural lesions that can be observed at the 
spinal MRI. The most frequent and specific lesion which might be found in SpA 
patients is the BMO of the anterior vertebral corners, an expression of anterior 
osteitis [198]. Another type of lesion found is the replacement of vertebral corners 
with fatty tissue (fatty lesions), although it seems to be less specific for SpA and of 
later appearance[199-201]. The presence of BMO in the posterior vertebral corners 
(posterior osteitis) was found to be highly specific for this form of disease, but the 
possibility of using it as a diagnostic criterion is limited by its poor sensitivity. In 
accordance with the data obtained from previous studies, including 
ASAS/OMERACT MRI study group, in our work the prevalence and the type of 
lesions both of inflammatory and structural nature were analyzed in subjects with 
CBP and with diagnosis or suspicion of early axSpA. In our study population, a 
higher prevalence of BME lesions to respect than those of structural lesions, has 
been highlighted at MRI, demonstrating the peculiar capacity of this method in the 
visualization of inflammatory lesions. A significant prevalence of BME lesions in 
MRI was observed for both SIJ and for the spinal district, with predominant 
localization in the vertebral anterior corner. This observation, in accordance with 
the data already reported in previous studies, highlights the importance of spine 
involvement, from the initial phases of the inflammatory process in axSpA [31, 200, 
211, 212]. This data appears to be interesting especially in the nr-axSpA forms 
without signs of sacroiliitis on MRI, and the inclusion of positivity for spine BME 
lesions at MRI among the classification criteria for axSpA would allow to include 
subjects with probable SpA. In some studies [201, 213-216], it has been shown that 
the determination of at least two inflammatory lesions (BME) in the anterior 
vertebral site (anterior spondylitis) in subjects younger than 45 years increases the 
likelihood for the diagnosis of axSpA. However, it has been highlighted that other 




non-rheumatic diseases involving the rachis may present similar patterns similar at 
MRI, e.g Scheuermann disease, septic spondylodiscitis, erosive osteochondrosis 
and other degenerative discs of the intervertebral disc [217-220]. The determination 
of multiple (at least three) structural lesions, such as fatty lesions, also increases the 
probability of having an axSpA [221], although in other studies it has been observed 
that the prevalence of these lesions tends to increase with increasing age and is also 
significant in healthy subjects or with other degenerative or non-rheumatic vertebral 
diseases [217-220]. Therefore, the inclusion of positive MRI of the spine among 
classification criteria is currently under discussion, as a reduction in specificity 
could be observed in favor of increased sensitivity. In our work, the spine MRI also 
showed a high prevalence of inflammatory signs attributable to enthesitis (47 
patients), especially in the thoracic district (58%) [222]: this aspect of imaging 
suggests early involvement of this site in the initial phases of axSpA, since in our 
series 50 patients had a confirmed diagnosis of axSpA. From data reported in the 
literature so far, it is not clear whether the localization of MRI lesions can be 
correlated also to the site of axial pain [35,36]. In our work we showed a significant 
association between dorsal and gluteal pain and the location of inflammatory 
lesions (BME) in the thoracic spinal region and in the buttocks [222]. This data 
could suggest that the characteristics and the site of axial pain (thoracic and buttock) 
can be used as a specific predictive index for the positivity of inflammatory lesions 
on MRI. This association between the pain site and the localization of alterations 
on MRI is less striking for structural lesions, which was significant only for buttock 
pain and structural lesions of SIJ. The radiological progression of SIJ and the spine 
was also evaluated in terms of SIJ mNY and mSASSS scores from T0 to T24, 
according respectively to the definitions provided by Dougadas [208] and 
Poddubnyy [209]: we did not observe any significant variation. The absence of 
radiographic progression of the rachis and sacroiliac was probably due to the 
reduced sample size, the presence of a cohort that did not completely satisfy the 
criteria for axSpA and the limited duration of the observation period. The variations 
in time from T0 to T24 of the radiological activity level measured in terms of 




ΔSPARCC-SIJ and ΔSPARCC-spine were also taken into consideration: there was 
no significant reduction in the score either in total patients or in individual cohorts, 
although there was a reduction trend in the 2 cohorts that met the ASAS criteria for 
axSpA. These results can be justified by two possible reasons: 1) the early onset of 
CBP or these axSpA forms; 2) the excessively short follow-up time (24 months) to 
observe significant changes in radiological terms. The tendency to SPARCC score 
reduction in the 2 cohorts that met the axial ASAS criteria is attributable to the 
pharmacological treatment undertaken after baseline evaluation and the diagnosis 
of axSpA. However, due to non-homogeneity in therapy and reduced sample size 
(n = 54 patients) to T24 imaging, it was not possible to conduct a comparison 
analysis on the ΔSPARCC-SI and ΔSPARCC-spine degree between patients 
divided by type of treatment. Several studies have systematically evaluated the 
concomitant use of the spine and pelvis MRI in patients with suspected axSpA and 
healthy subjects controls. Some of these [90,192] have shown that a simultaneous 
evaluation of the spine and SIJ on MRI can determine an increase in the diagnostic 
capacity. However, other authors who have not confirmed this observation [41] 
state that the combined use of spinal and pelvis MRI only moderately increases the 
level of diagnostic probability in patients with suspected axSpA, because of the 
inclusion of false positives. In fact, other rheumatic diseases involving the spine 
such as Scheuermann's disease, spondylodiscitis, erosive osteochondrosis and other 
degenerative diseases of the intervertebral disc, may show similar patterns on MRI 
[36]. Even the appearance of multiple structural lesions (at least three), just as fatty 
lesions, increases the probability of axSpA [221], although, according to other 
studies, the prevalence of these forms of lesions tends to increase with aging and 
can be significant even in healthy individuals or affected with other spinal 
degenerative diseases. Patients with non specific LBP and healthy subjects may 
have some signs suggestive of SpA such as fatty lesions on spinal MRIs [217-221]. 
According to Weber et al. [41] using a MRI of the SIJ alone is less sensitive but 
more specific than the combined use of the spinal  and pelvis MRI, while inclusion 
of a spinal MRI leads to increased sensitivity and reduced specificity. The cost and 




time necessary to carry out MRIs cannot, in any case, be ignored. In our study 
population the prevalence of patients with spinal MRI lesions in absence of SIJ 
involvement was considered: eighteen patients (24%) with inflammatory lesions on 
spinal MRIs showed no abnormalities on SIJ MRIs, while 11 (14.7%) patients with 
sacroiliitis on MRI did not present lesions on spinal MRIs. Our data seem to indicate 
that the use of spinal MRIs together with SIJ MRIs can add further, relevant 
information during both the diagnostic process and the therapeutic follow-up. We 
also evaluated the presence of predictors of radiological progression and of 
radiological activity on MRI in our population: the early age onset of IBP, a long 
duration of IBP, increased inflammation indices, an higher use of NSAIDs, male 
sex and the presence of HLA B27 were identified as predictors, in accordance with 
the data already reported in the literature [50,51]. 
The current study investigated if there were differences in the clinical indices of 
disease activity commonly used in clinical practice in relation to the presence or 
absence of signs of sacroiliitis on plain radiographs and on MRIs. Although a 
significant difference was found in the three cohorts with regard to the prevalence 
of sacroiliitis on MRIs and X-rays and on the SPARCC SIJ score, we did not find 
any differences in clinical and disease activity indices. Higher indices were not 
found in the patients with active sacroiliitis on MRI with respect to those without 
inflammatory changes in the SIJ or with initial signs of radiographic sacroiliitis. 
This result may depend on both the early stages of axSpA and the small sample 
size. In fact, several studies [88-90,92,93,223] reported higher values of clinical, 
functional and disease activity indices in AS and r-axSpA, in patients with long 
disease duration with respect to subjects with nr-axSpA. Our study results also 
uncovered at T0 a significant correlation between inter- and intra- clinical and 
disease activity indices and between ESR and hs-CRP, as reported in literature 
[88,89]. The correlation between serological MMP3 levels and mSASSS, indicative 
of metalloproteinases’ role in the bone formation process, was an interesting finding 
and it is in accordance with the data described by Maksymowych et al. [137] who 
reported that independently of other indices, serum MMP3 levels could predicted 




two-year radiographic progression in 97 axSpA patients. Our data also showed that 
MMP3 correlates with other inflammatory, functional and disease activity indices 
(such as CRP, BASFI and BASDAI) and it is increased in the serum of patients 
with active axSpA, in agreement with previous studies [132,135-137]. It has been 
shown that MMP3 correlates with disease activity indices even in PsA [140]. As 
reported by Maksymowych et al., anti-TNF treatment induces a significant decrease 
in serum MMP3 levels as well as in ESR and BASDAI [137]. Van Kuijk et al. [141] 
who studied 24 SpA patients who were randomized to receive 40 mg of adalimumab 
once every 14 days or placebo found a reduction in serum MMP3 levels after only 
4 weeks after the onset with anti -TNFα therapy, while no change was noted in the 
serum levels of the placebo group. The molecule was elevated in active forms of 
SpA or in cases presenting important clinical involvement, supporting the 
hypothesis that MMP-3 could represent a reliable marker of disease activity.  The 
correlation between mSASS values and serum biomarkers should be evaluated by 
prospective studies.   
Recently, several studies have focused on the research and evaluation of 
interleukins (IL) involved in the pathogenesis of SpA [137]. IL-6 and IL-1 are the 
most widely studied proinflammatory cytokines [88,101,107,108], produced by a 
variety of immune cells and implicated in the production of a series of acute phase 
proteins such as amyloid serum A and the CRP. These two mediators are involved 
in the initiation and maintenance of the inflammatory process by stimulating the 
migration and proliferation of neutrophils at the site of inflammation and by 
regulating the activation and differentiation of T lymphocytes. Some recent studies 
have shown associations of IL-1 and of IL-6 with other interleukins with role of 
biomarker of inflammation [101,107,108]. Among these, IL-17 and IL-23 are key 
cytokines in the Th17 pathway [115-128]. A series of studies have reported that 
elevated levels of IL-17 and IL-23 are found in plasma and serum of patients with 
AS, which are associated with a higher degree of disease activity [69,109,112,113]. 
On the contrary, other studies have not confirmed this observation [114]. In our 
study we assessed whether there were significant differences in IL-17, IL-22 and 




IL-23 levels at T0 in the three cohorts of patients (axSpA Imaging Arm +, axSpA 
Clinical Arm +, not full ASAS axSpA) and no difference was detected. The 
absence of any significant differences in serum concentration of the studied 
biomarkers in the patients as having radiographic disease and non radiographic 
disease with or without MRI pelvis positive findings is primarily due to the very 
early stage of the disease (inflammatory low back pain≥3 months and <2 years) and  
secondary due to the very small size samples for single groups. It has also to be 
underlined that the inclusion criteria for this study were primarily the presence of 
inflammatory LBP and clinic/immunogenetic and imaging SpA features, in 
accordance with ASAS criteria, while the study population was divided in three 
cohorts only afterwards,  following the characteristics evidenced on imaging 
(presence or absence of SIJ involvement in MRI and X-Rays and of spine 
involvement in MRI). Another possible reason for the absence of elevated serum 
levels of inflammatory markers such as CRP and ESR may be the fact that 
inflammation is restricted to specific tissue compartments and does not extend to 
the systemic circulation and/or lymphoid organs in axSpA. Accordingly, previous 
studies reported that the immupathology of affected tissues and inflammatory 
alterations were not always reflected in the peripheral blood compartement 
[224,225]. These findings are similar to those reported in other study [150]: the 
authors did not find differences of some biomarkers levels in patients with early 
axSpA versus “control”back pain patients. We did not find a significant correlation 
of IL-17 and IL-23 values with other serological, clinical and disease activity 
indices. Therefore, the dosage of these biomarkers appears to be just indicative in 
the early stages of the disease, differently from IL-22 levels which correlated with 
some clinical indices, such as BASFI, BASG1, HAQ, VAS pain [94]. In some 
studies [139,226,227], conducted on patients with other forms of SpA, such as PsA, 
elevated levels of IL-22 expression have been reported and the correlation of this 
molecule with clinical and disease activity indices suggest its inflammatory role in 
the peripheral synovitis and in the diffuse skin psoriasis. However in our study, no 
significant correlation was found between skin involvement and serum levels of IL-




22, because patients with psoriasis had a very narrow skin involvement or only 
onicopathy with PASI <1. Higher IL-22 levels even in the axial form of SpA might 
suggest that it plays a role in active sacroiliitis. However, in our study population, 
we did not find increased IL-22 levels in patients with active sacroiliitis compared 
to patients without inflammatory changes of SIJ on pelvis MRI or in patients with 
radiographic sacroiliitis [94]. It would be interesting to evaluate if there is a 
correlation between the IL-22 levels and the presence/absence of active sacroiliitis 
on a larger sample size.   
During the follow-up from T0 to T24, in all patients, a significant reduction 
offunctional and disease activity indices was observed MASES (p=0.008), BASG1 
(p=0.02), BASG2 (p<0.0001), HAQ (p=0.0002), VASpain (p=0.01), VAS pain 
night (p=0.04), VAS disease activity (p=0.05), BASFI  (p=0.02), ESR (p=0.04), 
BASDAI (p<0.0001), ASDAS (p<0.0001). On the other hand, BASMI and CRP 
did not decrease significantly. There were no differences in the serological markers 
(ILs, MMP3 and hsCRP) values during the 2 years follow up period in the three 
groups. Considering,  patients subdivided among the 3 cohorts, we observed a 
downward trend for all functional indices (HAQ, BASFI, BASG1, BASG2, VAS 
pain, VAS night pain and VAS disease activity) and disease activity indices 
(BASDAI, ASDAS), which in some cases was statistically significant, particularly 
in two cohorts (axSpA Imaging Arm +, axSpA Clinical Arm +), but no more 
markedly significant decrease of these indices levels was observed in one cohort 
than the others. The improvement of the clinical, functional and disease activity 
indices is probably due to the pharmacological therapy undertaken after the 
diagnosis of axSpA, at the sametime it was observed a reduction of prevalence of 
inflammatory lesions (BME) on spinal and pelvis MRI, whose prevalence had 
decreased during the follow-up period.  An accurate analysis of the above-reported 
indices in relation to the type of therapy was not possible, due to the reduced sample 
size and the diversification of the treatment in the three cohorts.  
 
 





It has become increasingly urgent to detect axSpA in its earliest stages in order to 
initiate treatment as early as possible. MRI can detect inflammatory lesions and 
signs of active disease process even before structural bone damage has occurred. 
Pelvis MRI has recently been included in the ASAS classification criteria whose 
positivity is defined on the basis of the exclusive presence of inflammatory signs of 
SIJ. It remains a matter of debate whether the inclusion of inflammatory and 
structural lesions of spinal MRIs in the ASAS classification criteria could help to 
identify patients with suspected axSpA. A high prevalence of inflammatory lesions 
on MRIs of the SJI and of the spine (anterior osteitis and enthesitis) were found in 
our patients. As inflammatory lesions on spinal MRIs can occur in the absence of 
SIJ involvement, the use of spinal MRIs together with SIJ MRIs may add further, 
relevant information to the diagnostic process, especially with regard to nr-axSpA 
patients without signs of sacroiliitis on MRI.  A standard radiograph of the pelvis 
continues to be a crucial step in the diagnostic investigation in patients with 
suspected axSpA, especially in those with a longer history of symptoms. Studies on 
the involvement of the thoracic spine, which has until now never been considered 
by methods scoring spinal structural damage, are warranted. A significant 
involvement of the thoracic region was noted in the patients studied. 
In the current study in early axSpA patients with different types of axial 
involvement (presence or absence of radiographic sacroiliitis and of active 
sacroiliitis on pelvic MRI), significant differences in clinical severity, disease 
activity indices, and in biomarker levels were not found in the three patient cohorts. 
ILs, MMP3 and hs-CRP values were not significantly higher in any of the cohorts 
and were not correlated to radiographic SIJ involvement. A significant correlation 
between IL-22 and some disease activity indices and between MMP3 and hs-CRP 
were instead noted. The importance of early diagnosis and treatment of axSpA has 
been highlighted by many studies. Although the utility of some genetic and 
serological markers in diagnosing AS and axSpA, in monitoring disease activity, 




and in predicting patients most at risk for poor outcome has been investigated by 
numerous researchers, ESR and CRP have proven to be inadequate parameters for 
monitoring SpA activity [150]. Our data suggest that the disease processes, driving 
axial spondyloarthritis are not reflected by alterations in the peripheral blood 
compartment. Limits of this study are due to the small sample size and to the early 
disease stage (low back pain ≥3 months, ≤2 years, onset < 45 years). Further studies 
are warranted to assess in a more exhaustive manner the validity and reproducibility 
of the disease activity biomarkers considered here in identifying and monitoring 
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 3c 3d 
Image 3a. Sacroiliitis grade I Image 3b. Sacroiliitis grade II 
Image 3c. Sacroiliitis grade III Image 3d. Sacroiliitis grade IV 




         
 
        
 
4 5 
Image 4. Straightening of the cervical column Image 5. Squaring of vertebral body of C7 
Image 6. Erosion of anterior corner of 
vertebral body of L4  
6 
Image 7. Fusion of vertebral bodies of C2-C3  
7 




             
 
               
              
Image 8. Syndesmophytes of thoracic district 
of  T12-L1 
10a 
10b 
Image 9. Parasyndesmophytes of thoracic 
district of T11-T12-L1-L2 e squaring of 
vertebral bodies of L2-L3-L4 
 8 9 
Image 10a. Calcification of  the anterior 
longitudinal ligament (sign of the "bamboo 
cane") 
Image 10b. Calcification  of the anterior 
longitudinal ligament, of the inter-
apophyseal joints  and inter-spinous 
ligaments (sign of the "cog railway") 




        
  
 
     
   
11 12 
13 
Image 13. Bilateral sclerosis and erosions of 
SIJ, with main involvement of the right SIJ, 
in sequence T1 
Image 12. SIJ bilateral bone oedema, with 
greater phlogistic involvement of the right SIJ, 
in STIR sequence 
Image 11. Bone oedema of both SIJ, with main 
inflammatory involvement of left SIJ and with 
signs of sclerosis on right SIJ (STIR sequence) 
14 
Image 14. Initial sclerosis and some areas of 
adipose metaplasia of both SIJ in sequence T1 




             
 
              
15 16 
Image 15. Spondylodiscitis at the level of 
L5-S1 in sequence T1 
Image 16. Spondylodiscitis at the level of L5-
S1 in sequence STIR 
17 
Image 17. Osteitis of anterior-superior 
corner of C6, of anterior-lower corner of T6 
and anterior-superior corner of T7. Signs of 
enthesitis of D1-D5 district in STIR 
sequence 
18 
Image 18. Signs of enthesitis  of D5-D11 
district in STIR sequence 




         
 
                 
 
19 20 
Image 19. Osteitis of anterior-superior 
corner of L3-L4-L5 in sequence STIR 
Image 20. Osteitis of anterior-superior corner 
of L3-L4-L5 in sequence T1 
 21a 21b 
Images 21a e 21b. Anterior spondylitis. a) hyperintense signal from anterior osteitis from T12 to 
L3 in the STIR sequence (white arrows). b) corresponding hypointense signal in the same 
locations in sequence T1. Hyperintense signal at the antero-superior corner of T12 (white 
arrowhead) from adipose metaplasia 
